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Abstract 
Background: 
Pulmonary tuberculosis (PTB) remains a major concern worldwide. Although PTB is curable, both the disease and 
its treatment may have considerable medical, social and psychological consequences which may result in a 
decreased quality of life and functioning. Characterization of the functional capabilities of PTB patients post-
treatment and the impact of PTB on their quality of life may identify a need for more holistic management of PTB 
treatment that extends beyond microbiological cure. 
Methods: 
Firstly, an in-depth scoping review was conducted using the following key words: Pulmonary tuberculosis (MESH 
term) and Health related quality of life (HRQoL), Pulmonary tuberculosis (MESH term) and Spirometry and 
Pulmonary tuberculosis (MESH term) and Six minute walk test or 6MWT to review the current literature reporting 
on the HRQoL, lung function measurements and exercise capacity of a PTB population (Chapter 2).   
Secondly, a cross-sectional, quantitative, descriptive study was conducted. The study setting included five primary 
health care facilities (PHCF) in the Breede Valley sub-district of the Cape Winelands East District, Western Cape, 
South Africa. Adult patients diagnosed with PTB, 18 years and older and who were successfully managed through 
the Cape Winelands District Health Care system were considered for the study if they had least two negative 
sputum sample results and had completed at least five months of anti-tuberculosis treatment. Post treatment 
bronchodilator lung function tests, health related quality of life using the BOLD core questionnaire and six minute 
walk test distance (6MWD) was measured.  
Findings: 
The comprehensive broad search of the literature yielded a total of 2446 articles. A total of 2422 articles were 
excluded since the title; abstract or full text article did not conform to the review question or were eliminated as 
duplicates across databases. Twenty-seven articles divided amongst the three subsections i.e. PTB and HRQoL 
(n=13), PTB and Spirometry (n=9) and PTB and exercise capacity (n=6), were included in the review. 
In the cross-sectional study, 328 names were obtained from the TB registers of the five included PHCF of which 45 
patients were included in the study (56% male; mean age, 39.88±10.20 years). The majority of patients (n= 206; 
63%) were not contactable, and could not be recruited. Approximately half the total sample, (n=23; 52%) presented 
with normal lung function while n=11 (25%) presented with a restrictive pattern, n=9 (21%) presented with an 
obstructive pattern and only n=1 (2%) presented with a mixed pattern (defined as FEV1<80% predicted, FVC<80% 
predicted and FEV1/FVC<0.7). The mean six minute walk distance (6MWD) was 294.5m±122.7m. Respondents 
scored poorly on all sub-domains of the SF-12v2 except vitality. Role emotional and role physical scored lowest with 
mean scores of 28.1 and 35.27 respectively, while vitality scored the highest with 52.78.  
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Conclusion 
The findings of this thesis suggest that even after microbiological cure, PTB patients may suffer from a decreased 
quality of life, impaired lung function and a decreased exercise capacity. Specific challenges to data collection in a 
rural region were identified; which included patient recruitment, field testing of exercise capacity (6MWD), and the 
generalizabilty of standardized questionnaires in rural regions. The findings of this pilot study serves to inform the 
planning of a larger observational study, in the rural Cape Winelands of the Western Cape, South Africa. 
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Opsomming  
Agtergrond 
Pulmonêre tuberkulose (PTB) wek wêreldwyd steeds groot kommer. Hoewel dit geneeslik is, kan die siekte sowel 
as die behandeling daarvan beduidende mediese, maatskaplike en sielkundige gevolge hê, wat lewensgehalte en 
funksionering kan knou. Die tipering van PTB-pasiënte se funksionele vermoëns ná behandeling sowel as die 
impak van PTB op hul lewensgehalte kan dalk dui op ’n behoefte aan die meer holistiese bestuur van PTB-
behandeling, wat méér as blote mikrobiologiese genesing insluit. 
Metodes 
Eerstens is ’n diepgaande bestekstudie aan die hand van die volgende trefwoorde onderneem: pulmonêre 
tuberkulose (MeSH-term) en gesondheidsverwante lewensgehalte (HRQoL), pulmonêre tuberkulose (MeSH-term) 
en spirometrie, en pulmonêre tuberkulose (MeSH-term) en die ses minute lange stapafstandtoets (6MWT). Na 
aanleiding daarvan is die huidige literatuur oor die HRQoL, longfunksiemetings en oefenvermoë van ’n PTB-
populasie bestudeer (hoofstuk 2). 
Tweedens is ’n kwantitatiewe, beskrywende deursneestudie onderneem. Die studie-omgewing het bestaan uit vyf 
fasiliteite vir primêre gesondheidsorg in die Breedevallei-subdistrik van die streek Kaapse Wynland-Oos, Wes-
Kaap, Suid-Afrika. Volwasse pasiënte van 18 jaar en ouer wat met PTB gediagnoseer is en suksesvol deur die 
distriksgesondheidsorgstelsel van die Kaapse Wynland-streek bestuur word, is vir die studie oorweeg indien 
minstens twee van die pasiënt se sputummonsters TB-negatiewe resultate opgelewer het en die persoon reeds 
minstens vyf maande vir tuberkulose behandel is. Studiemetings het ingesluit brongodilator-longfunksietoetse ná 
behandeling, gesondheidsverwante beoordelings van lewensgehalte met behulp van die BOLD-vraelys, en die 
aflegging van ’n ses minute lange stapafstandtoets (6MWT).  
Bevindinge 
Die omvattende breë soektog van die literatuur het 'n totaal van 2446 artikels opgelewer. 'n Totaal van 2422 artikels 
is uitgesluit, aangesien die titel; abstrakte of volledige teks artikel het nie voldoen aan die navorsings vraag, of is 
uitgeskakel as duplikate oor databasisse. Sewe en twintig artikels verdeel tussen die drie onderafdelings, naamlik 
PTB en HRQoL (n = 13), PTB en Spirometrie (n = 9) en PTB en oefening kapasiteit (n = 6), is ingesluit in die 
oorsig. 
In die deursneestudie is 328 name uit die TB-registers van die vyf ondersoekpersele bekom. Altesaam 45 pasiënte 
(56% mans; gemiddelde ouderdom 39.88±10.20 jaar) is by die studie ingesluit. Die oorgrote meerderheid pasiënte 
(n = 206; 63%) kon nie bereik word nie, en dus ook nie gewerf word nie. Ongeveer die helfte van die algehele 
steekproef (n = 23; 52%) se longfunksie was normaal; n = 11 (25%) het ’n restriktiewe patroon getoon; n = 9 (21%) 
’n obstruktiewe patroon, en slegs n = 1 (2%) ’n gemengde patroon (wat omskryf word as ’n FEV1-
voorspellingswaarde van <80%, ’n FVC-voorspellingswaarde van <80%, en FEV1/FVC van <0.7). Die gemiddelde 
afstand wat in die ses minute lange staptoets afgelê is (6MWD), was 294,5 m±122,7 m. Respondente behaal swak 
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op al die sub-domein van die SF-12v2 behalwe vitaliteit. Rol emosionele en rol fisiese behaal laagste met die 
gemiddelde tellings van 28.1 en 35,27 onderskeidelik, terwyl vitaliteit behaal die hoogste met 52,78. 
Gevolgtrekking 
Die bevindinge van hierdie tesis gee te kenne dat PTB-pasiënte selfs ná mikrobiologiese genesing dalk swakker 
lewensgehalte, verswakte longfunksie en ’n afname in oefenvermoë ondervind. Bepaalde uitdagings vir data-
insameling in ’n landelike omgewing is uitgewys, onder meer pasiëntewerwing, veldtoetsing van oefenvermoë 
(6MWD) en die veralgemeenbaarheid van gestandaardiseerde vraelyste in landelike gebiede. Die bevindinge van 
hierdie proefstudie kan gebruik word om die beplanning van ’n groter waarnemingstudie in die landelike Kaapse 
Wynland-streek in die Wes-Kaap, Suid-Afrika, te rig. 
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Chapter 1: Introduction 
The following thesis reports on the lung function, HRQoL and exercise capacity of a microbiologically cured PTB 
population in a rural setting in the Western Cape, South Africa. This thesis is intended to serve as a baseline to inform 
the planning of a larger study in the same region. The thesis is presented in four chapters. The final chapter contains 
appendices which are intended to support or provide more detail to the thesis.  
Background 
Global efforts in the fight against PTB have yielded positive results. Since 2003 the worldwide incidence per capita 
has been falling with treatment success rates slowly rising1. South Africa is flagged as one of the 22 high burden 
countries, contributing approximately 8% of the total global burden of all TB cases2. South Africa has the seventh 
highest TB incidence in the world2. In accordance to world trends, South Africa’s cure rates and treatment success 
rates have increased from 66% in 2000 to 70% in 20072. This figure, however, is well below the stipulated figure set 
by the World Health Organisation (WHO) of 85%. 
PTB has long been associated with chronic respiratory symptoms, dating back to 1846 when Hutchinson first tested 
the vital capacity of TB patients3. The idea received very little research attention possibly due to the success of 
treatment in the 1960’s onwards in developed countries4. Increased efforts to measure the global burden of diseases 
and its impact on quality of life (QOL), has resurrected the interest in PTB and its sequelae4. Increased attention to 
chronic obstructive pulmonary disease (COPD) in both rich and poor countries could also be a major contributor to 
the spark of interest in PTB. A study by Snider et al.(1971) identified that heavy smoking and more severe TB 
independently increased the presence of airflow obstruction by approximately twofold, while the effect was additive 
but not synergistic in the presence of the two factors1,5. Thus, the focus of more recent studies has shifted more 
towards the non-tobacco related causes, of which PTB is now recognized as an important contributor to chronic 
airflow limitations in countries with high TB prevalence4. 
PTB and COPD share similar pathophysiological characteristics. The subsequent development and progression of 
disease, seen in both PTB and COPD, result in characteristic destructive parenchymal changes to lung tissue6. 
Destruction of the extra-cellular matrix which comprises of collagen and elastic and is integral to the structure of the 
lung may be the common pathological link between the two diseases7. Normal lung function requires alveolar support 
by the extra-cellular matrix and in many pulmonary diseases, abnormal remodelling or destruction of the extra-
cellular matrix is caused by the matrix metalloproteinase (MMP)7. MMP’s are a family of zinc dependent protease 
enzymes capable of destroying the extra-cellular matrix6. MMP’s have the ability to cause significant host damage 
and thus are tightly regulated. However, in diseases where there is altered or unregulated MMP activity damage to 
lung architecture is severe7. The antigenic wall component of mycobacterium tuberculosis stimulates the release of 
MMP-9 as well as up regulating genetic expression of MMP-1 and MMP-96. Parenchymal lung damage central to 
the development of cavitation often complicating active PTB is the result commonly seen by clinicians6.  Similarly, 
studies have found increased levels of MMP-8 and MMP-9 in tobacco related COPD6. It would thus be expected that 
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changes to the extra-cellular matrix would predominantly involve lung parenchyma rather than the airways in both 
PTB and COPD6.  
Despite the known structural changes to lung tissue resulting in sequeale associated with PTB, no treatment programs 
currently exist which recognizes these physiological and clinical changes that take place in PTB. The focus of most 
governmental strategies to combat the PTB epidemic is on microbiologic markers and outcomes such as cure, 
mortality and treatment completed/failure8. The impact of COPD on patients’ lung function and quality of life is well 
recognized by the literature, but little attention is given to the impact of PTB after microbiological cure.  
Thus, the aim of this thesis is to describe the lung function, exercise capacity and HRQoL of a cured PTB population.  
Outline of Thesis 
The following thesis will be presented in “masters by publication” format 
Chapter 1 introduces the reader to the burden of disease caused by PTB, the link between PTB and chronic obstructive 
pulmonary disease (COPD), as well as the rationale for conducting the study.  
Chapter 2 provides an in depth scoping review of the current literature pertaining to PTB and HRQoL, PTB and lung 
function and PTB and exercise capacity (specifically measured by the 6-minute walk test). 
Chapter 3 is the main article chapter which is a cross sectional, observational study which aims to describe the lung 
function, exercise capacity and HRQoL of a cured PTB population in a rural setting entitled:  
An Investigation into the health related quality of life (HRQoL) and functional assessment of a cured Pulmonary 
Tuberculosis (PTB) population in the Breede Valley District, South Africa: a pilot study  
Please Note: 
Chapter 3 (Article) has been presented according to the requirements of the journal in which the authors are intending 
to publish (BMC Public Health)  
The bibliography for the entire thesis is listed at the end of the thesis. Therefore, bibliographic information 
continues throughout the thesis. This will be amended before publication of the article (Chapter 3). 
In Chapter 4, the findings of the thesis are critically reviewed and discussed. The limitations and challenges faced 
during the data collection phase are unpacked and further elaborated on with mention of suggestions for future 
research. 
Lastly, Chapter 5 provides a list of appendices including data not represented in Chapter 3 as well as raw data 
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1.1 Significance of this study 
This study offered a unique opportunity to determine the burden of disease and health related quality of life (HRQOL) 
in a cured TB population. This study serves a base study for the further development of a multidisciplinary, strategic 
approach to the optimization of interventions in the rural community.   
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Chapter 2: Literature Review 
2.1 Introduction 
The link between pulmonary tuberculosis (PTB) and chronic obstructive pulmonary disease (COPD) 
has recently re-surfaced as a point of interest amongst researchers 9. Studies have shown that early and 
partially treated PTB can result in airflow limitation 10. Studies with longer follow-up periods have 
shown that in many cases, patients who have completed PTB treatment, have evidence of permanent 
airflow obstruction or restrictive impairment 10. PTB can lead to pulmonary scarring and a decline in 
lung function 11. In the PLATINO (Proyecto Latinamericano de Investigación Obstrucción Pulmanar)11 
and the PREPCOL (Pravalencia de EPOC en Columbia)11 studies, which are population-based surveys 
to estimate the prevalence of COPD using spirometry, a report of previous PTB or previous PTB 
treatment was strongly associated with the development of COPD as defined by the Global initiative 
for Chronic Obstructive Lung Disease (GOLD) criteria 11.  
There are distinct differences in the epidemiology of PTB between developing countries and first world 
countries 12. In developed countries, where strategies to control the disease has led to a decline in the 
incidence of PTB, the annual risk of infection is low with most new cases resulting from endogenous 
reactivation of remote infection acquired when the disease was more prevalent. The majority of new 
cases therefore occur in the elderly (≥65 years) 12. However, in countries where the standard of living 
is low, and health resources are scarce, the risk of new case infection is high and 80% of cases involve 
persons in their economically productive years (15-59 years) 12.  
In the Western Cape, one of nine provinces in South Africa, the incidence of TB is 909/100000 2, 
making it the province with the single highest incidence of TB in South Africa 2. Approximately 90% 
of new smear positive cases falls within the economically active age group 13. The emergence of multi-
drug resistant strains of TB and co-infection with Human Immuno deficiency Virus (HIV) has greatly 
complicated the management and control of TB 12. Co-infection with HIV is the strongest known risk 
factor for both immediate and delayed progression from infection to active TB 12. The risk of 
progression to disease for co-infected persons is 5%-10% per year compared with a 5%-10% lifetime 
risk for HIV negative persons 12. Fuelled by colliding disease epidemics, PTB notifications are now 
more prevalent between the ages of 20 and 40 years 14. 
South Africa is flagged as one of the 22 high burden countries, contributing approximately 8% to the 
total global burden of all PTB cases 2and that PTB has long been associated chronic airflow limitations 
in countries with high tuberculosis prevalence 9. However, few studies have analysed the impact of PTB 
on HRQoL, exercise capacity and lung function immediately after completion of PTB treatment. 
Therefore, the aim of this scoping review is to search the literature for relevant studies pertaining to 
PTB and health-related quality-of-life (HRQoL), exercise capacity as measured by the six minute walk 
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test (6MWT) and lung function as measured by spirometry. This review is intended to provide an 
overview of the literature and possibly serve as a base to inform the planning of future studies. 
Following an initial scan of the literature and consultation with experts in the field, the initial broad 
research question was defined as follows: How does PTB affect lung function, HRQoL and exercise 
capacity in a cured, post-PTB population?   
2.2.1 Methods of Review 
A scoping review was undertaken using the methodological framework originally outlined by Arksey 
and O’Malley from York University in the United Kingdom15.  The “York framework” suggests five 
stages to performing this type of review. The five stages are: Identification of the research question to 
be addressed; identification of the studies relevant to the research question; selection of studies to be 
included in the review; charting of the information and data within the included studies and collating, 
summarizing and reporting on the results of the review. An optional sixth phase of this methodology 
type, consultation with stakeholders, was not undertaken in this review.  
2.2.2 Search strategy 
A comprehensive search of PubMed, Cochrane Library, Cinahl, Biomed Central, Web of Science and 
Scopus was conducted using the following key words: Pulmonary tuberculosis (MESH term), Health 
related quality of life or HRQoL, Pulmonary tuberculosis (MESH term) and Spirometry and Pulmonary 
tuberculosis (MESH term) and Six minute walk test or 6MWT.  Due to time limitations and a lack of 
resources, articles were limited to those published in English.  
2.2.3 Article Selection 
In order to identify relevant articles, the search terms were divided into 3 sub-sections i.e. PTB and 
HRQoL, PTB and Spirometry and PTB and exercise capacity. Articles were screened for those 
specifically pertaining to PTB. Articles published in English, on an adult population (over 18 years old) 
diagnosed with either PTB or latent PTB and addressing either 1 or more of the above mentioned 
outcomes were included in the review. Cost-analysis studies, case reports and letters to the editor were 
amongst the articles which were excluded from this review. The principal reviewer assessed the titles 
and abstracts of the articles. When the titles or abstracts did not clearly indicate whether an article 
should be included or excluded, the full text was assessed and a second reviewer was consulted for 
opinion on whether the article should be included in this review. 
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2.2.4 Charting Process 
Descriptive data including general citation information, country of origin, type of study, clinical setting, 
primary objective, results of study and author’s conclusion were extracted from the included articles 
and charted in a MS Excel spreadsheet to create a database. Information gathered from the articles will 
be discussed narratively and data are summarized in tables and figures where applicable. 
2.3 Results  
The comprehensive broad search yielded a total of 2446 articles. A total of 2422 articles were excluded 
since the title; abstract or full text article did not conform to the review question or were eliminated as 
duplicates across databases. Twenty-seven articles divided amongst the three subsections i.e. PTB and 
HRQoL (n=13), PTB and Spirometry (n=9) and PTB and exercise capacity (n=6), were included in the 
review. 
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Figure 2.1 depicts the flow diagram of articles included and excluded for the key words; PTB and health 
related quality of life or HRQoL. Table 2.1 summarizes the included articles for PTB and health related 
quality of life. Although 13 articles were included, 1 article was a systematic review and thus was not 
included in table 2.1. The findings of the systematic review were thus discussed narratively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Flow Chart of Pulmonary Tuberculosis AND Health Related Quality of Life or HRQoL
Initial Hits from database 
inception n=489 
Duplicates across databases 
eliminated n=11 
Titles selected 
n=478 
Eliminated due to Age, 
Language and Title 
n=456 
Abstracts selected 
n=22 
Full text articles excluded - 
Cost analysis studies and 
Pharmacology studies n=9 
Full text articles included – Articles evaluating HRQoL as a primary 
or secondary outcome specifically in a TB population n=13 (total) 
Of those selected: 
Systematic Review n=1 (not included in table 2.1) 
Non-randomised Control n=1 
Prospective Cohort n=5 
Cross Sectional n=5 
Case Study n=1 
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Table 2.1: Overview of Studies on PTB and HRQoL 
Author Year Study 
Design 
Country Patients Gender HRQol 
Tool 
Standardised Comparison Conclusion 
Aggarwal  et 
al 
2013 Prospective 
 
India Pulmonary 
Tuberculosis 
Male and 
Female 
WHOQoL-
BREF 
 Category I treatment 
regimen or smear positive 
with Category III regimen 
HRQoL is impaired in patients with PTB, and improves 
rapidly and significantly with program based treatment. 
Ahmed 
Awaisu et al 
2012 Non-
Randomised 
Malaysia Pulmonary 
Tuberculosis 
Male and 
Female 
EQ-5D  PTB on DOTS with PTB on 
DOTS and smoking 
cessation included 
An integrated PTB-tobacco treatment strategy could 
potentially improve overall quality of life outcomes 
among PTB patients who are smokers 
Atif M et al 2012 Case Study Malaysia Pulmonary 
Tuberculosis 
relapse due 
to DMII 
Male  SF-36v2  None Relapse of PTB might be due to poor glyceamic control 
and malnutrition 
Babikako et al 2010 Cross 
Sectional 
Uganda Pulmonary 
Tuberculosis 
and HIV 
Male and 
Female 
MOS  None Domains worst affected in patient category Start of Treatment, 
2 Months on Treatment and Completed 
Perceived Health 
Bodily Pain 
Quality of Life 
Chamla, D 2004 Prospective 
 
China Pulmonary 
Tuberculosis 
Male and 
Female 
MOS SF 36  PTB with Control SF-36 scores are low in PTB patients indicating a decline in 
HRQoL, however, scores increase over the course of 
treatment 
Deribew,Amare 
et al 
2009 Cross 
Sectional 
Ethiopia Pulmonary 
Tuberculosis 
and Latent 
Tuberculosis 
Infection 
Male and 
Female 
WHOQoL HIV 
and Kesler 
Scale 
 None Domains worst affected at time of Survey: 
Pain 
Anxiety 
Mobility 
Godoy M.D. et 
al. 
2012 Cross 
Sectional 
Brazil Multi-Drug 
Resistant 
Tuberculosis 
Male and 
Female 
Airways 
Questionnaire 
20 
 None 78% patients reported a decrease in their Quality of Life 
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Key: =Yes;  EPTB=Extra Pulmonary Tuberculosis; LPTBI=Latent Pulmonary Tuberculosis Infection; PTB=Pulmonary Tuberculosis; HRQoL=Health Related Quality of Life 
Author Year Study 
Design 
Country Patients Gender HRQol 
Tool 
Standardised Comparison Conclusion 
Kruijshaar, 
M.E. et al 
2010 Prospective 
 
England Pulmonary 
Tuberculosis 
Male and 
Female 
HRQoL 
SF-36v2, EQ-
5D, VAS 
 
Anxiety 
STAI-6 
 
Depression 
CES-D 
 None PTB patients suffer from significantly diminished HRQoL 
at diagnosis. Treatment improved pts health scores within 
2 months, but this is still below the UK norms 
Lemos et al 2012 Cross 
Sectional 
Brazil Pulmonary 
Tuberculosis 
and HIV 
Male and 
Female 
HAT-Qol  None Domains worst affected at  time of Survey: 
 
Sexual Activities 
Financial Concern 
Secrecy 
Marra CA et al 2008 Prospective 
 
Canada Pulmonary 
Tuberculosis 
and Latent 
Tuberculosis 
Infection 
Male and 
Female 
SF-36v2 and 
DI(Back 
depression 
index) 
 None Active PTB patients had large improvements in most 
HRQoL domains by 6 months, however, when compared 
to LPTBI and US norms, HRQoL was still low at completion 
Othman G.Q. 
et al 
2011 Prospective 
 
Yemen Pulmonary 
Tuberculosis 
and Extra 
Pulmonary 
Tuberculosis 
Male and 
Female 
DR-12 Short 
Form 
 PTB with EPTB At the start of treatment, PTB patients have significantly 
lower HRQoL than those with extra PTB. Both groups of 
pts HRQoL improves after onset of treatment 
Pasipanodya et 
al 
2007 Cross 
Sectional 
USA Pulmonary 
Tuberculosis 
and Latent 
Tuberculosis 
Infection 
Male and 
Female 
St Georges 
Respiratory 
Questionnaire 
  Domains Worst Affected at time of Survey: 
Symptoms 
Activities 
Impact 
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2.3.1 Pulmonary Tuberculosis and Health-Related Quality-of-Life 
Descriptive data were extracted from the 12 eligible studies on PTB and HRQoL, summarised and 
expressed in Tables 2.1 and 2.2. All included studies were published between 2004 and 2013. Five of 
the 12 studies incorporated a cross-sectional study design and five articles incorporated a prospective 
study design. The study by Awaisu et al (2012) was the only study to utilize a non-randomized control 
design16. Three studies were conducted at a public hospital, four studies at a clinic and one only 1 study 
used both public and private hospitals. The studies by Godoy et al (2012) and Aggarwal et al (2013) 
carried out the studies at the Laboratory of Respiratory Physiology, University of Rio de Janeiro and 
microscopy centres, patients’ homes and multiple directly observed therapy short-course (DOTS) 
centres, respectively8,17. The total number of participants recruited for all studies were n=2123, with 
Aggarwal et al (2013) including a total of n=675 in a study conducted in India8. Participants of the 
studies were between 15 years and 70 years. Studies by Babikako et al (2010), Marra et al (2008), 
Awaisu et al (2012), Jotam et al (2007) and Godoy et al (2012) all reported age as a mean with standard 
deviation16-20. The study by Aggarwal et al (2013) was the only study not to mention age range or a 
mean with standard deviation8. Eight of the 12 studies were conducted in third world countries while 
the studies by Pasipanodya et al (2007), Marra et al (2008) and Kruijshaar et al (2010) were conducted 
in the USA, Canada and England respectively19-21.  
2.3.2 Tools and Outcomes 
All of the included studies made use of standardized HRQoL tools and three of the twelve studies 
validated standardized HRQoL tools in their local population.  All included studies evaluated HRQoL 
as either a primary or secondary outcome measure.  The studies by Marra et al (2008) and Kruijshaar 
et al (2010) both added depression indexes as secondary outcome measures19,21.  HRQoL tools and 
domain characteristics are tabled in Table 2.1.
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2.3.3 Results of Pulmonary Tuberculosis and HRQoL 
The average patient treatment time for tuberculosis across all of the included studies was 7.45 months. 
Godoy et al (2012) evaluated patients after an eighteen-month treatment regimen for multi-drug 
resistant tuberculosis and only evaluated patients who were sputum clear at the twelve month mark17. 
Six studies, including a case study by Atif et al (2012), evaluated patients at their initial diagnosis, after 
the intensive phase of treatment and again after treatment completion8, 16, 19, 21-23. Lemos et al (2012) and 
Pasipanodya et al (2007) only evaluated their subjects after completion of treatment20, 24. Both Othman 
et al (2011) and Kruijshaar et al (2010) evaluated their subjects HRQoL at initial diagnosis and at one 
month into treatment21, 25. However, Kruijshaar et al (2010) added an extra quality of life data collection 
point at the end of treatment21. Deribew et al (2009) was the only study to report on patients’ quality of 
life after the intensive phase of their tuberculosis treatment alone26. 
A wide variety of generic instruments were used to report on HRQoL. The SF-36 questionnaire was 
used most (n=4; 30% of included studies). The SF-36 is a short form questionnaire adapted from the 
longer Medical Outcomes Survey questionnaire. It comprises of 36 items which is divided into eight 
domain subscales including Physical Functioning (PF), Role Physical (RP), Bodily Pain (BP), Vitality 
(VT), General Health (GH), Social Functioning (SF), Role Emotional (RE) and Mental Health (MH). 
From these domains, a physical component summary (PCS) and mental component summary (MCS) 
score can be calculated. Kruijshaar et al (2010) used both the SF-36v2 and the European Quality of life 
(EQ-5D) in a United Kingdom population and validated these against the Visual Analogue Scale (VAS) 
21. Awaisu et al (2012) was the only other study to use a validated EQ-5D questionnaire in the Malaysian 
population16. Deribew et al (2009) and Aggarwal et al (2013) both used the World Health Organisation 
Quality of Life (WHOQoL) questionnaire, while Godoy et al (2012) and Lemos et al (2012) used the 
Airways Questionnaire 20 and the HIV/AIDS Targeted Quality of Life (HAT QoL),respectively8,17,24,26. 
The long Medical Outcomes Survey was used by Babikako et al (2010), who validated it against the 
VAS in a local population18. The only study to use a disease specific tool was the study done by Othman 
et al (2011), who used the DR-12 short form25. The DR-12 short form is a PTB specific questionnaire 
developed and validated in an Indian population and first reported on in 200327. The questionnaire 
comprises of 12 items and covers PTB symptoms, socio-psychologic factors and exercise adaptation.  
All of the included studies reported a decrease in patients’ HRQoL. Godoy et al (2012) reported that 
78% of patients with multi-drug resistant PTB suffered from a decreased HRQoL17. Lemos et al (2012) 
and Awaisu et al (2012) both reported on a decrease in HRQoL in patients co-infected with both PTB 
and HIV when compared to PTB alone16,24. Six of the twelve studies, who all recorded quality of life at 
multiple stages of tuberculosis treatment, reported that HRQoL was poor at the start of treatment, but 
improved as the tuberculosis treatment progressed. Characteristics of the domains that showed the most 
improvement during the course of tuberculosis treatment for the various HRQoL tools are presented in 
Table 2.2. In general, physical health and bodily pain/pain are the most frequently reported domains to 
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have improved across all HRQoL tools. A comparison of domains measured and domains best improved 
at follow-up are tabulated in table 2.2. 
2.3.4 Reviews 
Guo et al (2009) published a systematic review entitled: Measuring health-related quality of life in 
tuberculosis: a systematic review28. Six electronic databases were searched including MEDLINE, 
EMBASE, Cochrane Library, PsychInfo, CINAHL and HaPI using the keywords tuberculosis, quality 
of life, quality adjusted life years, health utility, health status, life quality and well-being. An initial 
literature search identified 2540 articles of which 12 were included in the review after inclusion and 
exclusion criteria. Marra et al (2008), Chamla et al (2004) and Pasipanodya (2007) were the only three 
studies that overlapped with this scoping review19, 20, and 23. This scoping review included 9 articles which 
were published after 2009. Keywords and databases searched also differed between the scoping review 
and the systematic review. 
2.3.5 Discussion and Conclusion of the effect of Pulmonary Tuberculosis on HRQoL 
Traditionally, medical outcomes were measured using objective clinical indicators such as 
physiological tests and disease status. However, a gradual shift in this philosophy has led to the 
inclusion of the patients’ perspective in the evaluation of medical outcomes29. A need arose to assess 
health status beyond the traditional indicators of morbidity and mortality 23. HRQoL measurements are 
important for assessing the impact of the chronic disease and its treatment on patients29.  
The results of this scoping review on HRQoL agree with the findings of the systematic review by Guo 
et al (2009)28. Guo et al (2009) concluded that tuberculosis has substantial adverse impacts on patients’ 
quality of life, even after they have been deemed cured28.  The findings of this review suggest that 
patients perceived HRQoL is decreased in all patients diagnosed with PTB. The quality of life does 
improve as pharmacological treatment progresses. However, Marra et al (2008) concluded that even 
though there was an increase in reported HRQoL, these scores were still lower than the population 
normal or those patients with latent tuberculosis infection19. Kruijshaar et al (2010) also noted that 
HRQoL scores had increased by the two-month mark of pharmacological treatment but these too were 
decreased when compared with the population normal values21. 
It appears that the domains worst affected from when patients are diagnosed, with TB, are physical 
health and bodily pain, but these were also the two domains that rapidly improved as treatment 
progressed. Mental and social domains seemed to not improve for a longer period time, sometimes even 
after the patient is deemed cured. Tuberculosis is however a disease that is associated with lower socio 
economic status and is more prevalent in middle to low income countries 30. Therefore, reasons for the 
prolonged decrease in psychological and mental domains could be attributed to environmental and 
social factors such as the stigmatism associated with the disease. 
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Evident from this review is the wide variety of HRQoL tools used in the studies included. The 
systematic review by Guo et al (2009) suggested that a standardized HRQoL tool be developed for TB 
to assess changes in health status as the disease treatment progresses28. However, six of the 12 studies 
in this scoping review utilized the SF-36 or derivatives thereof, and were able to identify changes in TB 
patients’ perceptions of health. This suggests that the SF-36 is sensitive enough to detect changes in 
HRQoL in a TB population. Othman et al (2011) used the DR-12 questionnaire which is a PTB specific 
questionnaire developed in India and first reported in 200325. The questionnaire has however not been 
used in many other populations to date. Guo et al (2009) also noted that the DR-12’s validation process 
was not conducted in a systematic fashion and the evidence for the validity of the questionnaire was not 
convincing28.  
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Table 2.2: Comparisons of Domains best Improved of HRQoL before PTB treatment, intensive phase of PTB treatment and after PTB treatment 
Author HRQoL 
Tool 
Used 
Validity 
and 
Reliability 
Standardised Domain 
Measured 
at Initial 
Diagnosis 
Domain Improvement After Intensive Phase/1st 
Follow-up 
Domain  Improvement at 
End of Treatment 
Domains 
Best 
Improved 
Aggarwal A et al WHOQoL-
BREF 
3 of 24 items 
had 
Spearman’s ρ 
coefficient 
>0.60 and 8 
items >0.75 = 
good 
convergent 
validity  
Cronbachs 
α=>0.70 
 Physical, 
Psychological, 
Social 
relationships 
Environment 
Physical 
Psychological 
Social relationships Environment 
 
 
 
 
Physical 
Psychological 
Social relationships 
Environment 
 
 
 
 
Physical, 
Psychological, 
However, these 
domains were 
significantly 
lower amongst 
sputum positive 
patients and 
among those on 
Category I 
treatment 
compared with 
Category III 
patients 
Ahmed Awaisu 
et al 
EQ-5D Validated by 
EuroQoL 
group UK for 
use in 
Malaysian 
population 
 Mobility 
Self care 
Usual 
activities 
Pain 
Anxiety 
Mobility 
Self care 
Usual activities 
Pain 
Anxiety 
 
 
 
 
 
Mobility 
Self care 
Usual activities 
Pain 
Anxiety 
 
 
 
 
 
Pain, Anxiety, 
Mobility 
Improvement in 
both DOTS 
group and 
smoking 
cessation DOTS 
group 
Atif M et al SF-36v2 n/a  PF 
RF 
BP 
GH 
VT 
SF 
PF 
RF 
BP 
GH 
VT 
SF 
 
 
 
 
 
 
PF 
RF 
BP 
GH 
VT 
SF 
 
 
 
 
 
 
Improvement in 
all domains 
however still 
under the 
Malaysian 
norms 
published by 
Azman et al. 
Quality of life of 
the Malaysian 
general 
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RE 
MH 
RE 
MH 
 
 
RE 
MH 
 
 
 
 
 
 
population: 
results from a 
postal survey 
using the SF-
36v2. Medical 
Journal of 
Malaysia, 
2003;58:694-
711 
Chamla, D MOS SF 36 SF-36 had 
item 
consistency 
ranging 0.56 
to 0.86 for 
PTB and 
Control 
Reliability 
Coefficients 
by Cronbachs 
α ranged 0.88 
to 0.97 
 PF 
RF 
RE 
BP 
VT 
SF 
MH 
GH 
PF 
RF 
RE 
BP 
VT 
SF 
MH 
GH 
 
 
 
 
 
 
 
 
PF 
RF 
RE 
BP 
VT 
SF 
MH 
GH 
 
 
 
 
 
 
 
 
PF,BP, GH 
 
All physical 
scales increased 
in PTB group 
significantly 
over course of 
treatment 
compared to 
Control 
Kruijshaar, M.E. 
et al 
 
 
 
 
 
 
 
 
 
 
 
HRQoL 
SF-36v2, 
EQ-5D, 
VAS 
 
Anxiety 
STAI-6 
 
Depression 
CES-D 
 
n/a 
 
Reliability in 
this n at 
Diagnosis 
Cronbachs 
α=0.887 
 
 
Cronbachs 
α=0.894 
 PF 
RF 
BP 
GH 
VT 
SF 
RE 
MH 
PF 
RF 
BP 
GH 
VT 
SF 
RE 
MH 
 
 
 
 
 
 
 
 
PF 
RF 
BP 
GH 
VT 
SF 
RE 
MH 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
EQ-5D = 
Pain/Discomfort 
& Problems 
with self care 
Proportions of 
problems are 
larger than seen 
in UK norms 
 
SF-36v2 = RP, 
SF, MCS 
PCS & MCS 
significantly 
lower than UK 
norms at 
Diagnosis. 
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Key:  =Yes;  = No; PF=physical functioning; RP=role physical; BP=bodily pain; GH=general health; VT=vitality; SF=social functioning; RE=role emotional; MH=mental health
 
 
Author HRQoL 
Tool 
Used 
Validity 
and 
Reliability 
Standardised Domain 
Measured 
at Initial 
Diagnosis 
Domain Improvement After Intensive Phase/1st 
Follow-up 
Domain  Improvement at 
End of Treatment 
Domains 
Best 
Improved 
Marra CA et al SF-36v2 
and 
DI(Back 
depression 
index) 
n/a  PF 
RP 
BP 
GH 
VT 
SF 
RE 
MH 
PF 
RP 
BP 
GH 
VT 
SF 
RE 
MH 
 
 
 
 
 
 
 
 
PF 
RP 
BP 
GH 
VT 
SF 
RE 
MH 
 
 
 
 
 
 
 
 
VT, PF, RF, SF, 
RE 
 
Patients with 
active PTB had 
bigger HRQoL 
deficits than 
those with 
LPTBI when 
compared to US 
norms 
Othman G.Q. et 
al 
DR-12 
Short Form 
Reliability 
α=0.71 
Validity after 
translated in 
Arabic by 
distribution 
among 
doctors 
nurses and 
social 
scientists for 
content 
relevance 
 Symptoms 
Life activities 
Social 
activities 
Symptoms 
Life activities 
Social activities 
 
 
 
Symptoms 
Life activities 
Social activities 
n/a 
n/a 
n/a 
Symptoms, Life 
activities 
 
HRQoL 
improved 
significantly in 
PPTB and Extra 
PPTB groups 
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Figure 2.2 depicts the flow diagram of articles included and excluded for the key words; PTB and six 
minute walk test or 6MWT. Table 2.3 provides an overview of the included articles for PTB and 
exercise capacity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Flow Chart of Pulmonary Tuberculosis and Six-minute walk test (6MWT) 
 
2.4 Pulmonary Tuberculosis and Exercise Capacity 
Descriptive data were extracted from the six included studies and summarised and expressed in Table 
2.3. All of the included studies were published between 2003 and 2012. Five studies utilized an 
observational study design and one study including a prospective cohort17,31-34. Ando et al (2003) was 
the only study to utilize an intervention type design, reporting on 6MWT data at baseline and again 
Initial Hits from database 
inception n=1235 
Duplicates across 
databases eliminated n=2 
Titles selected 
n=1233 
Eliminated due to Age, 
Language and Title n=1226 
Abstracts selected 
n=7 
Full text articles excluded - 
Letters to editor, 
Pharmacology n=1 
Full text articles included 
– Articles reporting on 
6MWT specifically in a 
TB population n=6 
Stellenbosch University  https://scholar.sun.ac.za
  
 
33 | P a g e  
 
after an intervention35. Yoshida et al (2006) and Ando et al (2003) carried out their studies in Japan34, 
35. Miguire et al (2009) and Pontororing et al (2010) carried out their studies in Indonesia while 
Sivaranjini et al (2010) and Godoy et al (2012) carried out their studies in India and Brazil, 
respectively17, 31-33. Sivaranjini et al (2010) and Yoshida et al (2006) obtained their study sample from 
public hospitals where as Maguire et al (2009), Pontororing et al (2010) and Ando et al (2003) all used 
the clinic setting31-35. Yoshida et al (2006), Sivaranjini et al (2010) and Ando et al (2003) used a patient 
sample suffering from pulmonary tuberculosis sequelae (PTS). The total number of participants 
recruited for all the studies was n=365. The observational study by Pontororing et al (2010) yielded the 
most participants (n=164)32. Four of the six included studies evaluated either exercise tolerance/training 
as part of a pulmonary rehabilitation program as their primary outcome measure. The study by 
Pontororing et al (2010) compared current Indonesian management of TB with the standards set by the 
World Health Organisation (WHO) as their primary objective32. 
Table 2.3: Overview of PTB and Exercise Capacity 
 
Key: PTB=Pulmonary Tuberculosis; HIV=Human Immuno Deficiency Virus; COPD=Chronic Obstructive Pulmonary Disease
Author Study 
Design 
Year Country Setting Sample 
Size 
Comparison 6 Minute 
Walk Test 
Procedure 
Ando et al Non 
Randomized 
Trial 
2003 Japan Clinic n=64 PTB with COPD As described by 
Steele et al 1996 
Godoy et al 
 
Observational 2012 
 
Brazil 
 
Laboratory of 
Respiratory 
Physiology, 
University of Rio 
de Janeiro 
 
n=18 None According to ATS 
Guidelines 
Maguire et 
al 
Prospective 2009 Indonesia Clinic n=69 None According to ATS 
Guidelines 
Pontororing 
et al 
Observational 2010 Indonesia Clinic n=162 PTB with HIV and 
without HIV 
According to ATS 
Guidelines 
Sivaranjini 
et al 
Observational 2010 India Public Hospital n=60 PTB with Normal 
Population 
According to ATS 
Guidelines 
Yoshida et al Observational 2006 Japan Public Hospital n=10 None As described by 
Steele et al 1996 
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Table 2.4 summarizes the results of the 6 included articles on PTB and exercise capacity. 
Table 2.4: Results of PTB and Exercise Capacity 
Key: =Yes; =No; 6MWD – 6-minute walk distance; 6MWWD – 6-minute walk weight distance 
2.4.1 Results of PTB and Exercise Capacity 
Studies by Maguire et al (2009), Sivaranjini et al (2010), Pontororing et al (2010) and Godoy et al 
(2012) all used a 6MWT procedure as recommended by the American Thoracic Society 200231-33. 
Yoshida et al (2006) and Ando et al (2003) used the procedure for the 6MWT as described by Steele et 
al (1996), which does not vary to that described by the American Thoracic Society. All of the included 
studies assessed functional capacity either as a baseline measurement for patients diagnosed with PTB 
or as a comparison between PTB and HIV, COPD or population norms. Maguire et al (2009) reported 
on the six minute walk weight distance (6MWWD) at the start of treatment, two months into treatment 
and again at the end of treatment on newly diagnosed smear positive patients with no previous history 
of PTB31. Maguire et al (2009) saw a rise of 12.3% in 6MWWD from baseline to end of treatment31. 
Yoshida et al (2006) and Ando et al (2003) both reported an increase in six minute walk test distance 
(6MWD) after exercise34, 35. The studies by Sivaranjini et al (2010) and Godoy et al (2012) both reported 
decreased 6MWD when compared to a normal group or the percentage predicted in their respective 
studies17, 33. Yoshida et al (2006) was the only study to report on an increase in Modified Borg Scale 
dyspnoea and fatigue scores from baseline to after exercise intervention, while no improvement was 
seen in oxygen saturation and heart rate values34. 
Author Year Population Improvement 
in  6MWD or 
6MWWD 
Improvement 
in SPO2 
Improvement 
in Heart Rate 
Improvement 
in Dyspnoea 
Score 
Improvement 
in Fatigue 
Score 
Ando et al 2003 Pulmonary 
Tuberculosis 
Sequelae and 
Chronic 
Obstructive 
Pulmonary 
Disease 
 n/a n/a n/a n/a 
Godoy et al 
 
2012 
 
Multi-Drug 
Resistant 
Tuberculosis 
n/a n/a n/a n/a n/a 
Maguire et 
al 
2009 Pulmonary 
Tuberculosis 
 n/a n/a n/a n/a 
Pontororing 
et al 
2010 Pulmonary 
Tuberculosis 
n/a n/a n/a n/a n/a 
Sivaranjini 
et al 
2010 Pulmonary 
Tuberculosis 
Sequelae 
n/a n/a n/a n/a n/a 
Yoshida et 
al 
2006 Pulmonary 
Tuberculosis 
Sequelae 
     
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2.4.2 Discussion and Conclusion of PTB and Exercise Capacity 
The 6MWT is a simple, inexpensive and practical functional walk test that requires little technician 
training and basically only the ability to walk 33. The test has traditionally been used in patients suffering 
from chronic cardiac or respiratory illness and could be used as either a once off generic measure of 
functional status, or as an outcome measure from a rehabilitation program33. All six of the included 
studies used a 30 meter, inside corridor. 
The findings of this review indicate that overall, 6MWT distance is decreased in patients diagnosed 
with PTB when compared to normal walking distances. The impact of PTB on 6MWT distance varies 
depending on age and the severity of the disease. Sivaranjini et al (2010) concluded that PTB has a 
considerable impact on the functional capacity of older patients in India, while Ando et al (2003) noted 
that pulmonary rehabilitation is beneficial for patients with PTB, as in patients with COPD, if the 
severity of lung destruction in the diseases is similar33,35. The 6MWWD should be considered as an 
adjunct measure to distance alone as it is shown to correlate well for VO2max as well as aerobic 
threshold31. 
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Figure 2.3 depicts the flow diagram of articles included and excluded for the key words; PTB and 
spirometry. Table 2.5 provides an overview of the included articles for PTB and spirometry.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Flow Chart of Pulmonary Tuberculosis and Spirometry 
 
Eliminated due to Age, 
Language and Title n=673 
Abstracts selected 
n=20 
Titles selected 
n=693 
Duplicates across databases 
eliminated n=29 
Full text articles included 
– Articles reporting on 
spirometry as a primary or 
secondary outcome 
specifically in a TB 
population n=9 
Full text articles excluded - 
Case reports, Letters to editor 
Pharmacology and not 
reporting on spirometry n=11 
Initial Hits from database 
inception n=722 
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2.5 Pulmonary Tuberculosis and Spirometry 
Descriptive data were extracted from the nine included studies and summarised in Table 2.5. All of the 
studies were published between 1996 and 2012. Godoy et al (2012) carried out their study in Brazil, 
while the two studies done in the United States were both carried out by Pasipanodya et al (2007) and 
Pasipanodya et al (2012)17,20,36. Menezes et al (2007) used five Latin American countries in a multi-
centre study37. The remaining five studies were carried out in Spain, Canada, Korea, South Africa and 
Pakistan. Candela et al (1996) used a retrospective study design. Long et al (1998), de Villiers et al 
(2004) and Pasipanodya et al (2012) all used prospective study designs36,38-40. Menezes et al (2007) and 
Godoy et al (2012) both made use of cross-sectional study designs while Lee et al (2011) used a 
clustered, multi-stage cross-sectional design for a population based survey17,37,41. Pasipanodya et al 
(2007) was the only study to use a case-control design20. The total number of subjects tested for lung 
function across the studies was n=9889, with the population-based studies by Menezes et al (2007) and 
Lee et al (2011) yielding the highest number of patients at n=3687 and n=5571, respectively37,41. All of 
the studies included both male and female patients with an age ranging from <28yrs to >60yrs. Table 
2.5 provides an overview of articles included on PTB and spirometry. 
Table 2.5 Overview of included studies on PTB and Spirometry 
Author Year Study Design Country Population Sample 
Baig et al 2010 Descriptive Pakistan Past PTB n=47 
Candela et al 1996 Retrospective Spain EPTB n=81 
de Villiers et al 2004 Prospective South Africa MDR PTB n=33 
Godoy et al 2012 Cross Sectional Brazil MDR PTB n=18 
Lee et al 2011 Clustered Korea Past PTB n=3687 
Long et al 1998 Prospective Canada PTB n=25 
Menezes et al 2007 Cross Sectional Brazil, Uruguay, Mexico, Chile, Venezuela Platino Sample n=5571 
Pasipanodya et al 2007 Case Control USA PTB & LPTBI n=107 
Pasipanodya et al 2012 Prospective USA PTB n=320 
Key: MDR=Multi-Drug Resistant; PTB=Pulmonary Tuberculosis; LPTBI= Latent Pulmonary Tuberculosis Infection; EPTB=Extra 
Pulmonary Tuberculosis 
2.5.1 Results of Pulmonary Tuberculosis and Spirometry 
Due to the heterogeneity of the included studies, the results of Long et al (1998), Lee et al (2011) and 
Menezes et al (2007) were not included in the table, but will rather be described in narrative form. 
Spirometry results for the other included studies are described in Table 2.6.For the purposes of this 
review, the pattern of lung impairment was described as obstructive, restrictive or mixed and reported 
as percentages of the total study population.  
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Table 2.6: Results of PTB and Spirometry with Lung Function Classification 
Author Year Obstructive 
Pattern 
Restrictive 
Pattern 
Mixed 
Pattern 
Normal 
Baig et al 2010 55.3% 29.9% 14.8%  
Candela et al 1996 3% 10% not reported  
de Villiers et al 2004 12% 42% 39% 2% 
Godoy et al 2012 39% 22% 17% 22% 
Pasipanodya et al 2007 PTB 13% 31% not reported  
LPTBI 1% 15% not reported  
Pasipanodya et al 2012 10.75% 73.25% 16%  
Key: PTB=Pulmonary Tuberculosis; LPTBI=Latent Pulmonary Tuberculosis Infection 
The most predominant pattern of lung impairment across the studies is a restrictive pattern. However, 
Baig et al (2010) and Godoy et al (2012) both found the obstructive patterns to have higher population 
percentages in their studies17,42. Long et al (1998) reported on the relationship between lung structure 
(CT scan) and lung function (spirometry), with or without cavitation in a PTB population39. The results 
of the study by Lee et al (2011) are described in Table 2.741. 
Table 2.7: Spirometry (Lee et al 2011) Airflow obstruction as defined FEV1/FVC <0.70 
Total Sample n=3687 Percentage of Sample with Airflow Obstruction 
Previous PTB 27.9% 
No Previous PTB 6.5% 
Smoker 13.8% 
Never Smoker 4.7% 
 
Menezes et al (2007) extracted data for PTB from a much larger study looking at the burden of lung 
disease in Latin America called the PLATINO study37. In their multistage survey, they identified 
previous PTB as a risk factor for COPD.  
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A summary of the spirometry results are described in Table 2.8.  
Table 2.8: PTB and Spirometry (PLATINO) 
 
Key: PTB=Pulmonary Tuberculosis; FEV1= Forced Expiratory Volume in 1 second; FVC=Forced Vital Capacity 
The authors of the study found that the association of PTB with FEV1 values was stronger than that of 
FVC and as a result, the FEV1/FVC values showed a marked reduction, characteristic of an obstructive 
pattern.  
2.5.2 Reviews 
Two reviews were found during the literature search. The first was a systematic review entitled: A 
systematic review of the association between pulmonary tuberculosis and the development of chronic 
airflow obstruction in adults 43. The authors performed a search of the PubMed/Medline database and 
articles were excluded if; they did not contain original research,they had insufficient details of either 
the methodology or results to assess the validity of the findings and if the patients were on active PTB 
treatment without post treatment follow-up. Nineteen studies with a variety of study designs were 
included in the review. Four of the studies in the current review overlap with the studies included in the 
systematic review. Reasons for the small overlap of studies could be attributable to databases searched, 
difference in search terms and the specific inclusion and exclusion criteria of the systematic review. 
The authors concluded that the association between chronic airway obstruction (COA) and a history of 
PTB is positive. “However, whether PTB-associated COA should be considered part of the COPD 
spectrum, a phenotype of COPD or an unrelated disease remains unclear.” 43 
The second review identified in the literature search was conducted by Ehrlich in 2011 entitled: Chronic 
airflow obstruction and respiratory symptoms following tuberculosis: a review of South African 
studies9. The authors aimed to review population-based and occupational based South African studies 
that provides estimates of association between PTB, chronic symptoms and loss of lung function. The 
authors concluded that the studies reviewed contributed to the evidence of a strong association between 
PTB, even if properly treated, and subsequent airflow obstruction as well as restrictive loss. 
 
 
 
Total Sample n=5571 of which 132 has medical diagnosis of PTB 
 No Medical Diagnosis of PTB Medical Diagnosis of PTB 
Post Bronchodilator FEV1% of predicted 95.82+-17.4 91.43+-18.8 
Post Bronchodilator FVC% of predicted 98.12+-15.52 96.13+-16.34 
Post Bronchodilator FEV1/FVC% of 
predicted 
97.85+-10.0 91.79+-13.27 
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2.5.3 Discussion and Conclusion of PTB and Spirometry 
The association between PTB and lung function impairment has been around for several years 9. PTB 
has recently been identified as an independent risk factor for the development of COPD in major 
population based studies such as the PREPCOL and PLATINO studies37. Consequences of PTB include 
permanent scarring, bronchiectasis and pleural fibrosis43. During the treatment of active PTB, lung 
function impairment is usually restrictive in nature. This may persist or develop into an obstructive 
pattern43. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) identifies obstructive 
lung function impairment as FEV1/FVC <0.07. Despite the fact that PTB has been identified as a risk 
factor for the development of COPD through population based COPD screening studies, the spirometric 
values are often influenced by concurrent risk factor exposure such as smoking, biomass fuel exposure, 
dust and childhood respiratory illness; making it difficult to distinguish pure obstructive abnormalities 
from other lung structural abnormalities without full body pletysmography43. 
The findings of this review suggest that lung function impairment is evident after PTB. The severity 
and pattern of the lung function impairment varies according to how long after the patient is deemed 
cured the spirometry is done, the amount of times the person has been diagnosed with PTB and even 
the severity of the PTB itself. The review also suggests that lung function measurements appear to be 
dynamic in nature, with patients tested immediately after anti-tuberculosis treatment showing more 
restrictive pattern, but patients who have been deemed cured over 10 years ago presenting with sequelae 
and respiratory symptoms show more obstructive patterns. The results of this review agree with the 
findings of the systematic review by Allwood et al (2013) who confirmed a positive association between 
a past history of PTB and the presence of airflow limitation43. In a high PTB burden area such as South 
Africa, PTB as a contributor to the development of COPD is important to health care providers and 
policy makers as it appears that microbiological cure is only the start of what should be a dynamic, 
holistic management of both the active disease as well the sequelae there of. 
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2.6 Conclusion  
This broad, scoping review of the literature indicates that PTB patients suffer from a decreased HRQoL, 
impaired lung function and a reduced exercise capacity. Spirometric values are also reduced when 
compared with normal population values or patients with latent PTB infection. Despite a wide variety 
of HRQoL tools used in various studies, patients perceptions of their physical health, specifically the 
domains of bodily pain and physical functioning (as scored by the SF-36 HRQoL instrument), showed 
good improvement with anti-tuberculosis therapy, however, these scores were also below population 
normal scores. Therefore, this review highlights a need for continued intervention after tuberculosis 
drug therapy and serves as a good foundation to inform the planning of future studies in this patient 
population 
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Article Abstract 
Background: 
Pulmonary tuberculosis (PTB) remains a major concern worldwide. Although PTB is curable, both 
the disease and its treatment may have considerable medical, social and psychological consequences 
which may result in a decreased quality of life and functioning. Characterization of the functional 
capabilities of PTB patients post-treatment and the impact of PTB on their quality of life may identify 
a need for more holistic management of PTB treatment that extends beyond microbiological cure. 
Methods: 
A cross-sectional, quantitative, descriptive study was conducted. The study setting included five 
primary health care facilities (PHCF) in the Breede Valley sub-district of the Cape Winelands East 
District, Western Cape, South Africa. Adult patients diagnosed with PTB, 18 years and older and who 
were successfully managed through the Cape Winelands District Health Care system were considered 
for the study if they had least two negative sputum sample results and had completed at least five 
months of anti-tuberculosis treatment. Post treatment bronchodilator lung function tests, health related 
quality of life using the BOLD core questionnaire and six minute walk test distance (6MWD) was 
measured.  
Findings: 
 Of the 328 names obtained from the TB registers of the five included PHCF, 45 patients were included 
in the study (56% male; mean age, 39.88±10.20). The majority of patients (n= 206; 63%) were not 
contactable, and could not be recruited. Approximately half the total sample, (n=23; 52%) presented 
with normal lung function while n=11 (25%) presented with a restrictive pattern, n=9 (21%) presented 
with an obstructive pattern and only n=1 (2%) presented with a mixed pattern (defined as FEV1<80% 
predicted, FVC<80% predicted and FEV1/FVC<0.7). The mean six minute walk distance (6MWD) was 
294.5m±122.7m. Respondents scored poorly on all sub-domains of the SF-12v2 except vitality. Role 
emotional and role physical scored lowest with mean scores of 28.1 and 35.27 respectively, while 
vitality scored the highest with 52.78.  
Conclusion 
The findings of this study suggest that even after microbiological cure, PTB patients may suffer from 
a decreased quality of life, impaired lung function and a decreased exercise capacity. Challenges 
faced during this pilot study such as patient recruitment, 6MWD and the generalizabilty of 
standardized questionnaires in rural regions are crucial in the development of a larger study. The 
findings of this pilot study serves to inform the planning of a larger observation study, with matched 
case controls, in the rural Cape Winelands of the Western Cape, South Africa. 
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Background 
Tuberculosis (TB) is described as a social disease because it is closely linked to the issues of 
overcrowding, poverty and unemployment13. South Africa is burdened with one of the worst TB 
epidemics in the world and in the Western Cape; one of nine provinces in South Africa, the incidence 
of TB is 909/100000 13. Approximately 90% of new smear positive cases falls within the economically 
active age group 13. Fuelled by interacting epidemics like HIV, TB notifications are now more prevalent 
between the ages of 20 and 40 years 14. 
Despite many advances in modern medicines fight against TB, TB remains a major cause of death 
worldwide, especially in low-middle income countries 30. PTB has been identified as a risk factor for 
the development of chronic obstructive pulmonary disease (COPD)44. In the PLATINO
1 and the PREPCOL211 studies, reports of previous PTB or previous PTB treatment was strongly 
associated with the development of COPD as defined by the Global initiative for Chronic Obstructive 
Lung Disease (GOLD) criteria 11. Pathophysiologically, PTB has been hypothesized to result in 
sequelae which could affect a patients’ functional ability and impair lung function 17. In high incidence 
countries such as South Africa, a significant number of COPD cases are likely to be due to PTB 
sequelae, however, epidemiological studies documenting the prevalence of post –TB COPD still need 
to be conducted 45.   
The World Health Organisation (WHO) defines health as “a state of complete physical, mental and 
social “well-being” and not only “the absence of disease or infirmity” 46. Current government 
intervention strategies are focused on identification of new cases and bacteriological markers until 
outcomes such as cured, treatment completed or treatment failure/defaulted have been achieved 8. 
Although PTB is curable, both the disease and its treatment may have considerable medical, social and 
psychological consequences which may result in a decreased quality of life and functioning 21. Thus, 
the clinical burden of the disease may exist beyond the duration of the treatment of the infection 8. 
Characterization of the functional capabilities of PTB patients post-treatment and the impact of PTB on 
their quality of life may identify a need for more holistic management of patients presenting with PTB 
that extends beyond microbiological cure.  
Context: Baseline data is needed to plan the future physiotherapeutic management of PTB patients in 
the Overberg. Using a primary outcome of COPD prevalence a sample of 200 patients was deemed 
sufficient to detect a chronic obstructive pulmonary disease (COPD) prevalence of 15 % (95%CI 10%-
20%).  Sample size was calculated using FEV1 and FEV1/FVC prevalence proportion ratios based on 
Western Cape BOLD data 47. The BOLD study data identified a prevalence of obstructive airway 
disease in the Uitsig community (Cape Town, Western Cape) of 22% and found an association between 
                                                     
1 PLATINO - Proyecto Latinamericano de Investigación Obstrucción Pulmanar 
2 PREPCOL - Pravalencia de EPOC en Columbia 
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airway obstruction and a previous history of PTB. To inform the planning of a larger, observational 
study, a pilot study was undertaken.  The primary objectives of this paper is to describe the 
demographics, respiratory symptoms, pulmonary airflow patterns (using spirometry) health related 
quality of life and exercise capacity (using the six minute walk test) of patients from one sub-district. 
A secondary objective is to report on recruitment strategies needed to optimize patient recruitment in 
the region.  
Methods 
Ethical Considerations 
Ethical approval for the study was obtained from the Committee for Human Research at Stellenbosch 
University (S12/06/186). (Appendix A-4) Permission was obtained from the district Department of 
Health and all patients provided written informed consent prior to participating in the study. (Appendix 
A-1 and Appendix A-2) 
Design: Cross-sectional, quantitative, descriptive study. 
Sample Description 
Adult patients (18 years and older), diagnosed with PTB; and successfully followed up through the 
course of their treatment by the Cape Winelands District Health Care system, were considered for the 
study. Patients were included in the study if they had at least two negative sputum sample results and 
completed at least five months of anti-tuberculosis treatment.  Patients were excluded if they presented 
with haemoptasis, pneumothorax, unstable cardiovascular status, aneurysms, recent eye surgery, recent 
abdominal or thoracic surgery or did not provide consent.  
Setting: The Breede Valley is a sub-district of the Cape Winelands East District and has the town of 
Worcester at its centre. The Breed Valley District is a predominantly rural region about 112km from 
Cape Town central business district. Five primary health care facilities (PHCFs), (ie. Rawsonville 
Clinic, Worcester Clinic, Orchards Clinic, De Doorns Clinic and Touws River Clinic) were identified 
as sites for sputum sample collection in the region and were used for data collection. 
Training 
The PI is a qualified physiotherapist with six years of clinical and teaching experience in the field of 
cardio pulmonary physiotherapy. Prior to commencement of this study, the PI was trained in the 
spirometry maneuver, by lung function technicians at Tygerberg Hospital.  The manoeuvre was 
performed based on ATS guidelines 48. Prior to data collection, the PI was responsible for the training 
of the research assistant (RA) for the collection of body mass index, height and weight data as well as 
the execution of the six minute walk test according to ATS guidelines 49. 
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Measurements and Procedures 
Lung Function  
Post bronchodilator 47lung function tests were performed using the SpiroBank II (MIR, Roma Italy) and 
analyzed using the Win Spiro v4.4 software. European Respiratory Society (Economic Community for 
Coal and Steel) normal reference values were applied and these were corrected for race (African 
decent). The Spirobank II (MIR, Roma Italy) is a battery operated handheld automatic calibrated 
spirometer 50 which uses a reusable turbine sensor to measure both volume and flow. (Appendix B-3) 
The Spirobank II office spirometer meets ATS (diagnostic devices) recommendations for accuracy and 
precision for measuring both FEV1 and FVC 51, and was found to be a practical, compact and valid when 
compared to the Jaeger MasterScope laboratory spirometer.  For this study, calibration was checked at 
regular intervals using a 3l calibration pump and the deviation was not allowed to be more than 5% as 
per manufacturer recommendation. (Appendix C-7) The Spirobank II has been used in several studies 
50,52,53.  
The device was piloted by the PI, prior to data collection, on a normal, student population (n=3) for 
standardization of manoeuvre procedure and reproducibility of lung function measurements according 
to ATS guideline standards. (Appendix C-6) Each student performed a minimum of three spirometry 
manoeuvres. The results of which were all reproducible with 150ml for FEV1 and FVC.  
Health Related Quality of Life (The BOLD Core Questionnaire) 
The BOLD Core questionnaire was created from existing, validated questionnaires47. The questionnaire 
has been validated in BOLD studies, following a standardized methodology, around the world, 
including Cape Town, South Africa 47. The questionnaire also incorporates the SF-12v2 questionnaire, 
a shortened form of the SF-36v2, which is used to assess the patients HRQoL. The SF-12 has been 
validated in many studies and shows good correlation to the SF-36v2 54. The 12 items reflect the 
following eight sub-domains: self-perceived general health (GH), bodily pain (BP), physical 
functioning (PF), role physical (RP), vitality (VT), role emotional (RE), mental health (MH) and social 
functioning (SF). A physical health component summary score (PCS) and a mental health component 
summary score (MCS) was generated for each patient using the Quality Metric software scoring 
algorithm. The scores were then normalized to be comparable with a mean population score of 50. The 
lower the physical health score (PCS) or mental health score (MCS), the more activity limitation the 
person has. The questionnaire has been translated into Afrikaans, and tested in one sample within the 
Cape Metropole47. The questionnaire includes information on respiratory symptoms (cough, sputum, 
wheezing, shortness of breath) occupation, respiratory diagnosis (asthma, emphysema, COPD, chronic 
bronchitis, TB, etc.), co-morbidities, health care utilization, medication use, activity limitation and 
health status. Permission to use the questionnaire was obtained from BOLD (Appendix A-1) 
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The questionnaire was piloted, by the PI, on the first n=2 patients during data collection to assess 
patient’s general understanding of the questionnaire. Both patients understood the questionnaire and it 
was determined that the questionnaire would take 35-50 minutes to complete. The results were included 
and analysed with the study data. 
Exercise Capacity - The Six Minute Walk Test (6MWT) 
The 6MWT is a self-paced, submaximal measure of exercise capacity. During the 6MWT, patients 
choose their own intensity of exercise and are allowed to stop and rest during the test. The six-minute 
walk test (6MWT) is a valid, reliable, safe and cost-effective test to measure exercise capacity49. Several 
studies have used the 6MWT in a TB population 17, 31,32,34,35.  
The 6MWT was piloted, by the RA, on the first n=2 subjects during data collection to standardize the 
procedure according to ATS guideline standards49. The results were included and analysed with the 
main study data.  
Data Collection and Procedure 
Data were collected between December 2012 and August 2013. Patient names and contact details were 
obtained from the tuberculosis registers at the five clinics by the PI. The RA was responsible for 
telephonically contacting patients and scheduling appointments. If patients were unable to attend the 
clinic, the research team would set up appointments for data collection at their homes. Figure 3.1 shows 
the procedure for data collection at clinics and at patients’ homes. 
                 Clinic 
 
 
                 Home 
 
Figure 3.1: Procedure for data collection at clinics and patient homes 
 
Lung function data were collected by the PI using field spirometry. The spirometry maneuver was 
explained and fully demonstrated by the PI prior to execution by the patient. A minimum of three 
manoeuvre attempts were performed and attempts had to be reproducible within 150ml. Patients were 
given two minutes rest between manoeuvres or until their breathing rate returned to normal.  
6MWT data were collected by the RA. Patients had to walk standardized distances which were marked 
by two cones. Baseline and post-test heart rate (HR) and oxygen saturation percentage (SPO2%) were 
measured using the Nellcor Oximax N-65 portable pulse oximeter (Covidien Colorado USA). Patients’ 
Patient’s enter 
and sign 
consent (PI) 
Patients given 2 
puffs (200µl) 
salbutomol (PI) 
HRQoL (SF12v2) 
via BOLD 
Questionnaire 35-50 
min (PI) 
Lung Function 
Tests (PI) 
Weight, Height 
and 6MWT 
(20m) (RA) 
Weight, Height 
and 6MWT 
(10m) (RA) 
Stellenbosch University  https://scholar.sun.ac.za
 48 | P a g e  
 
dyspnoea and fatigue were measured before and after the execution of the test using the Modified Borg 
Scale. (Appendix B-10).  
The standardized 6MWT allows for a 30 meter track, however, due to space limitations within the 
community, distances had to be standardized to 20m at the clinics and further reduced to 10 m at 
patient’s homes. 
HRQoL data were collected by the PI using the BOLD core questionnaire. The questionnaire was 
administered by the PI in a private location. 
Data Management and Quality Control 
All data were entered electronically by the PI and was stored on a password protected laptop. Spirometry 
data were downloaded via USB to a research laptop and patient information was coded.  
Spirometry reports were checked by Prof. Irusen (Dept of Medicine, Stellenbosch University) for 
acceptability and reproducibility criteria According to ATS guidelines. The Spirobank II spirometer 
also has a built in instant quality report (on manoeuvre) with prompts as to what the patient is doing 
wrong. (eg. breathe all the air out of your lungs; breathe out faster etc.)  
 The RA used a quality control checklist (Appendix B-5) to ensure that the execution of the 6MWT was 
consistent. All encouraging commands to patients were uniform and spoken in a calm, monotone voice. 
Patients were informed of time intervals at 4 minutes, 2 minutes and at the end of the test.  
Statistical Analysis 
Data were analyzed using Statistica v11. Descriptive statistics were used to describe basic features of 
the data. Means and standard deviations were reported for normally distributed data. Where data were 
skewed, medians and interquartile ranges were reported. T-test analysis was used to compare the 
distances of patients who walked the 20m course vs those who walked the 10m course. A p value of 
<0.05 was used to determine statistical significance, if any. Analysis of SF12v2 data were analysed 
using Quality Metric Health Outcomes Scoring Software v4.5.  Patients’ data were removed from 
analysis if they could not successfully complete an outcome according to the study criteria or stipulated 
guidelines.  
Results 
A total 324 patient names were obtained from the folders at the five included clinics. Of these, 45 
patients were contactable and successfully recruited for the study (Figure 3.2). The majority of patients 
n= 206 (63%) were not contactable, for a variety of reasons (Figure 3.2), and thus could not be recruited. 
Descriptive characteristics of the 45 included patients are shown in table 3.1.  
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Table 3.1: Descriptive Characteristics of population 
Demographics  Total n=45 
Gender (male) % (n) 56% (n=25) 
Age (years) 39.88±10.20 
Race Coloured = 93% (n=42)             Black = 7% (n=3) 
Weight (Kg) 55.60 ±11.21 
Height (m) (mean & SD) 1.65 ±0.11 
BMI (Kg/m2) (mean & SD) 20.53±4.05 
Years of Formal Schooling (years) 7.8 ±3.52 
Respiratory Conditions or Symptoms  
Previously diagnosed with TB (%) 
Number of times diagnosed with TB (mean & SD) 
Diagnosed Emphysema (%) 
64.4% (n=29) 
1.86±0.63 
0% 
Diagnosed Asthma (%) 20% (n=9) 
Diagnosed COPD (%) 6.6% (n=3) 
Breathing problems interfered with ADL’s (%) 
Usually cough without a cold (%) 
Usually cough up phlegm (%) 
Have had wheezing in the last 12 months (%) 
35.5% (n=16) 
64.4% (n=29) 
73.3% (n=33) 
62.2% (n=28) 
Tobacco Use  
Smoking History (%) 78% (n=35) 
Cigarette Type (%) Manufactured = 57.14% (n=20) 
 
 
Occupational Exposure 
Hand Rolled = 25.71% (n=9) 
Both = 17.14% (n=6) 
 
Worked for longer than 1 year in a dusty job? (%) 
Worked in a dusty job and cigarette smoker (%) 
78% (n=35) 
17.1% (n=6) 
Co-Morbidities  
Heart Disease (%) 2% (n=1) 
Hypertension (%) 8% (n=4) 
Lung Cancer (%) 0% 
Stroke (%) 6% (n=3) 
Spirometry  
FEV1 % Predicted (Mean ± SD) 90.96±32.43  
FVC % Predicted (Mean ± SD) 83.15±35.54 
FEV1/FVC % Predicted (Mean ± SD) 93.71±14.64 
Obstruction Pattern (%) 21% (n=9) 
Restrictive Pattern (%) 25 % (n=11) 
Mixed Pattern (%) 2% (n=1) 
Normal Lung Function 52% (n=23) 
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The study sample comprised of 25 men and 20 women. The majority of the population classified 
themselves as coloured n=42 (93%) and the average years formal schooling was 7.8 ±3.52 years. Almost 
two thirds of the population (n=29; 64%) had previously been diagnosed with TB and n=4 (8%) had 
been hospitalized for breathing problems before they were 10 years old. Co-morbidities such as heart 
disease (n=1), hypertension (n=4) and stroke (n=3) were present in a total of eight patients. The mean 
BMI of 20.53±4.73 fell within normal range. Over three quarters of the population n=35 (78%) had a 
smoking history or had been exposed to occupational dust while only a small proportion n=6 (17%) 
were exposed to both. Only n=3 (6.6%) patients were previously diagnosed with chronic obstructive 
pulmonary disease. 
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Figure 3.2: Flow diagram of Patients included and excluded from the study 
HRQoL n=45 6 MWT n=42 Spirometry n=44 
Excluded: n=1 
Patient did not understand spirometry 
manoevre and results were not reproducible 
to within 200ml 
 
Excluded: n=3 
Patient could not perform the test due to unspecified 
illness at time of testing affecting the patient’s ability 
to ambulate (n=1) or the distance requirement at their 
homes were not sufficient (n=2) 
 
Total Names Obtained from Registers June 
2012 – March 2013 
n= 324 
Rawsonville Clinic 
n=35 
Patients included n=3 
Orchards Clinic n=16 
Patients Included n=5 
De Doorns Clinic n=78 
Patients Included n=19 
Worcester Clinic n=162 
Patients Included n=14 
Touws River Clinic 
n=33 
Patients Included n=4 
Patients Not 
Included n=148 
Reasons: 
- No contact 
number n=81 
-Died n=8 
- Moved Away 
n=11 
- Too sick n=8 
- Invalid Address 
n=21 
- Not Interested 
n=18 
- Gang Violence 
n=1 
Patients Not 
Included n=11 
Reasons: 
- No Contact 
number n= 11  
Patients Not 
Included n=32 
Reasons: 
- No Contact 
number n=25 
- Number does 
not exist n=3 
- Died n=1 
- Moved Away 
n=1 
- Not Interested 
n=1 
 
Patients Not 
Included n=59 
Reasons: 
- No Contact 
Number n=59 
Patients Not 
Included n=29 
Reasons:  
- No Contact 
number n=24 
- Number does 
not exist n=3 
- Too sick n=1 
- Under age n=1 
 
Total Patients recruited for the study n=45 
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Lung Function 
Of the 44 patients data analysed, just over half the sample, n=23 (52%) presented with normal lung 
function patterns, n=11 (25%) presented with a restrictive pattern, n=9 (21%) presented with an 
obstructive pattern and only n=1 (2%) presented with a mixed pattern (defined as FEV1<80% predicted, 
FVC<80% predicted and FEV1/FVC<0.7). A summary of the spirometry values is shown in Table 3.1. 
No significant associations were identified between respiratory symptoms of cough and FEV1 or 
between smoking or occupational dust exposure and FEV1. Spirometry results did not statistically differ 
between patients who identified themselves as smokers and those who did not. (Appendix C-1) Figure 
3.3 summarizes the categorization of COPD severity according to GOLD criteria of the present 
population (n=9).  Full spirometry results with GOLD classification are represented in Appendix C-5.  
 
Key: GOLD 1: FEV1 ≥ 80% predicted, GOLD 2:50% ≤ FEV1< 80% predicted, GOLD 3: 30%≤ FEV1< 50% predicted, GOLD 4: FEV1 < 30% 
predicted 
Figure 3.3: Categorization of Obstructive pattern according to GOLD criteria 
 
Exercise Capacity  
The mean (± SD) six minute walk distance (6MWD) for the 42 included patients (male n=24, 57.1%) 
was 294.05m ± 122.7m. The 6MWD was significantly shorter for patients who completed the 10m 
(n=27) course when compared to patients completing the 20m course (n=15) (p<0.001).  While 
physiological measurements of oxygen saturation (SPO2) and heart rate remained constant from baseline 
to post-test measurements, patients perceptions of dyspnea (p<0.001) and fatigue (p<0.001) changed 
from baseline to post-test measurement (Table 3.2). The 6MWD was not associated with age (p=0.279; 
r= -0.167) (Appendix C-4) or BMI (p=0.461; r= -0.113) (Appendix C-4).   
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Table 3.2: Results of 6MWT (Exercise Capacity) 
 Baseline Min 
Value  
Max 
Value 
End of Test Min 
Value 
Max 
Value 
p 
Value 
SPO2**                   (%) 96.93±3.9 82 100 96.95±2.41 89 100 0.964 
Heart Rate** 
(BPM) 
91.06±18.01 49 129 92.88±19.19 53 143 0.235 
Dyspnoea** 
(Modified BORG) 
0.79±1.33 0.0 4.0 1.48±1.64 0.0 5.0 0.001 
Fatigue**   
(Modified BORG) 
0.98±1.53 0.0 5.0 1.70±1.73 0.0 6.0 0.001 
Key: * = mean ±SD; ** = mean ± SD and pValue; SPO2: Oxygen saturation 
Health Related Quality of Life 
Respondents scored poorly on all sub-domains of the SF-12v2 except vitality. The mean summary scores 
obtained for both mental and physical health were lower than the population norm of 50. Role emotional 
and role physical scored lowest with mean scores of 28.1 and 35.27 respectively, while vitality scored 
the highest with 52.78. Both mental component score (MCS) and physical component score (PCS) were 
lower than the population norm. Patients’ perception of their mental health was worse than their 
perception of their physical health. (See Figure 3.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: SF12v2 Domain Scores  
 
Patient Recruitment Strategies 
Despite the fact that the PI communicated with all of the PHCF managers on patient availability during 
the planning phase of the study, patient recruitment presented a major problem. Violence and unrest in 
the district, lack of transport, lack of patient motivation and understanding, migrant labour and incorrect 
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patient contact details were documented reasons why patients did not attend clinics. TB nurses relied on 
either community workers or word of mouth to communicate with patients. Therefore, the research team 
developed individual recruitment strategies for each of the clinics. (Appendix B-2) When patients with 
valid contact details were unable to attend the clinic, the research team went door-to-door setting up 
appointments and collecting data.   
Discussion 
The findings of this pilot study suggest that patients who have completed anti-tuberculosis drug therapy 
and who are deemed cured may suffer from impaired lung function, a decreased exercise capacity and 
a decreased quality of life. However, the study also highlighted concerns with patient recruitment and 
the execution of outcomes measures in this rural environment. The information gathered in this pilot 
study will thus be valuable to inform the planning of future studies. 
Lung Function and Tuberculosis 
A little under half of the population presented with either airflow obstruction or an obstruction/restriction 
pattern at the end of their PTB treatment. There seems to be very little agreement in the literature as to 
the dominant lung function pattern associated with the disease. Godoy et al (2012) found obstruction as 
the most prevalent pattern at 39%17. Snider et al (1971) found 23% of the population with an obstructive 
pattern and 19% with a mixed obstruction/restriction pattern5. PTB is associated with lung tissue 
scarring which could result in restrictive patterns55. However, field spirometry may mask certain lung 
function abnormalities and full body plethysmography is needed for accurate diagnosis. 
Exercise Capacity and Tuberculosis 
6MWD was reduced in the present study. Studies by Sivaranjini et al (2010), Godoy et al (2012), 
Yoshida et al (2006) and Ando et al (2003) all reported reduced 6-minute walk test distances (6MWD) 
in PTB patients17, 33-35. Sivaranjini et al (2010) recorded a mean (±SD) 6MWD of 285.79±79.81meters 
in males and 245.5±73.11 meters in females33.   
The findings in the present study are similar to that of Sivaranjini et al (2010), and also found an overall 
reduced 6MWD in a cured PTB population. However, the aforementioned studies all used a 30m, indoor 
corridor to perform the 6MWT and distances varied between 245m and 415m33. Thus, it would appear 
that there is much variation in the distances achieved by patients post PTB treatment.  
Despite the reduction in the 6MWD in the present study, patients still managed to achieve distances 
comparable to those found in other studies with more controlled environments.  
 Casanova et al (2011) recorded a mean 6MWD in 444 healthy patients of 571±90m. This meant that on 
average, the patients had to turn 19 times during the test56. Patients in the present study turned an average 
of 19 times for those who walked 20m and 24 times for those who walked 10m. ATS guidelines 
recommend that the test should ideally be done indoors in a 30m straight corridor. Normative values 
have been established for this distance and distances usually exceeding 30m 57. In the primary care 
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setting, this is often not possible and space limitations force clinicians and researchers to modify the 
course length 57.   
Beekman et al (2013) evaluated the impact of a course length of 30m versus a course length of 10m on 
6MWD in COPD patients and found that a 10m course significantly shortens the distance that people 
with COPD achieve on the 6MWT57. Therefore, normative equations and predictors of morbidity and 
mortality of the 30m course cannot be assumed when using a 10m course 57. Factors such as patients’ 
poor health perception, understanding and lack of previous exposure to the 6MWT may have influenced 
the overall 6MWT results. A recent study by Bohonnan et al (2014) concluded that based on completion 
rates, distances walked, reliability and high correlation between distances walked over 2 minutes and 6 
minutes, the distance covered in the 2 minute walk test may be a considered a viable alternative to the 
distances covered in the 6MWT in community-dwelling individuals58. 
Health Related Quality of Life and Tuberculosis 
The results of the present study suggest that PTB does negatively impact on patients perceived HRQoL 
in both a physical and mental capacity. This result mirrors that of a systematic review which suggested 
that patients’ perception of their physical health appeared to be more affected by the disease but 
improved quickly with treatment. Perceptions of mental health, however, tended to persist well after 
patients were deemed microbiologically “cured”.   
Clinical Implications 
The results of this pilot study should be interpreted with caution. Adaptations to the 6MWT course were 
necessary in the rural environment. While our findings are similar to the reported 6MWD in a PTB 
population, normal reference values cannot be assumed for a reduced course length. Researchers should 
develop suitable reference values for a reduced 6MWD for use in the rural setting. 
Even though the researcher developed individual recruitment strategies for each of the PHCF’s, we were 
only able to recruit 45 patients. Future research should build on the strategies of the present study to 
optimize patient recruitment in the rural setting.   
Limitations to the Study 
There are limitations to the present study. Due to the small sample size, the results are not generalizable 
for the population. The BOLD Core Questionaire had never been used on a rural population before. This 
could have presented bias when patients answered the questions. Due to space limitations at both the 
clinics and the homes of the patients, the 6MWT course length had to be reduced and therefore 
established reference equations cannot be applied in this population. This study was however done as a 
pilot field study and offers realistic and pragmatic insight into the study population. 
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Conclusion 
The findings of this cross sectional pilot study suggest that patients who have completed anti-
tuberculosis drug therapy and who are deemed cured may suffer from impaired lung function, a 
decreased exercise capacity and a decreased quality of life. Future studies should investigate whether or 
not these patients would benefit from pulmonary rehabilitation. The data reported in this pilot study can 
inform the planning of a larger observational study in the Overberg region. 
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Chapter 4 
 
General Discussion 
This thesis set out to review the current literature and describe the characteristics of a cured pulmonary 
tuberculosis (PTB) population in terms of lung function measurements, health related quality of life 
(HRQoL) and exercise capacity in a rural community in the Breede Valley District of the Western Cape, 
South Africa. To date, no South African study has described this population. Previous studies, including 
the BOLD study47; have focused on lower social economic communities in the Cape Metropole of the 
Western Cape, South Africa. The findings of this study suggest that patients who have completed anti-
tuberculosis drug therapy and who are deemed cured may suffer from slightly impaired lung function, 
a decreased exercise capacity and a decreased quality of life. The results of this study therefore agree 
with a previous study by Godoy et al (2012) who described similar outcomes in a Brazilian population17. 
4.1 Tuberculosis and its impact on Quality of Life in South Africa 
In South Africa, the directly observed tuberculosis short course (DOTS) is implemented for the 
diagnosis and treatment of PTB. Despite the fact that the program has been around since 1995, cure rates 
in South Africa remain well below the World Health Organisations (WHO) recommendation of 85%. 
DOTS is almost strictly applied from a biomedical perspective and therefore, current TB literature is 
almost entirely written from that viewpoint30. The program mainly focuses on bacteriological markers 
and outcomes such as cure, mortality and treatment defaulted/failure8. Unfortunately, PTB patients do 
not only have to deal with the physical symptoms of the disease, but with the physiological, financial 
and psychosocial issues associated with the disease as well8. In high burden areas like South Africa, 
stigmatism and patients perceptions of the disease also contribute to the lack of successful management 
of the disease30. The symptoms and burden of disease therefore often extends to beyond chemotherapy 
or once a patient is deemed cured.  
The findings of this study are in alignment with the findings of the scoping review (chapter 2) in that 
patients who have completed anti-TB chemotherapy and who are considered cured continue to present 
with a decreased quality of life.  This study found that patient perceptions of mental health were lower 
than patient perceptions of physical health at the time of assessment. This is in contrast to a large 
population-based South African study by Louw et al (2012) who found that perceptions of physical 
health were lower than perceptions of mental health. This could be due to the fact that Louw et al (2012) 
measured patients’ quality of life one month into their PTB treatment59. Other studies (Godoy et al 2012, 
Kruijshar et al 2010) who measured patients’ quality of life at various stages throughout their PTB 
treatment, found that perceptions of physical health were lower at diagnosis, but rapidly improved as 
PTB treatment progressed17,21. However, perceptions of mental health continued to remain low even 
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after completion of PTB treatment60. Louw et al (2012) further identified predictors of good physical 
health as higher educational level, lower psychological stress, being diagnosed with less than three 
chronic illnesses and being HIV negative. Predictors of poor mental health were poverty, scoring low 
on the psychological distress scale and being HIV positive. In the present study, a small proportion of 
the population (16%) was diagnosed with co-morbidities but all had fewer than three, and the mean 
years of formal schooling was 7.8 years. These are all predictors of good physical health. However, 
poverty and unemployment was a huge issue in the present population and this could have contributed 
to their ongoing poor perception of their mental health status. The present study brings to light a global 
issue in the current approach to tuberculosis management. Although the WHO aims to eradicate the 
disease, the psycho-social issues that patients are left with remains a problem. A more holistic approach 
that provides patients with treatment options after microbiological cure is needed to truly deem a patient 
cured. 
4.2 Tuberculosis and Lung Function: Colliding Epidemics in a high burden setting 
A rise in the global burden of chronic obstructive pulmonary disease (COPD) has sparked recent 
research efforts to focus on the non-tobacco causes of COPD. Among these non-tobacco related causes, 
PTB has been marked as an independent risk factor for the development of COPD. Even though the 
aetiologies of the diseases are different, both result in pulmonary scarring which could lead to airflow 
limitations60. The results of this study found that just under half the population presented with lung 
function abnormalities. Pasipanodya et al (2007) found restriction to be the most predominant pattern 
five months into PTB treatment in a population in the United States20. There still seems to be much 
debate in the literature as to what the predominant lung function abnormality is related to PTB. However, 
there is definitely enough agreement to say that PTB patients do suffer from lung function abnormalities 
even once they have been deemed cured. 
Although not measured in the current study, it may be worth mentioning that pulmonary function 
abnormalities tend to persist or change after completion of TB treatment 43. In a study conducted on gold 
miners in South Africa, FEV1 and FVC values were found to be worse six months after treatment but 
stabilized 13 to 18 months after treatment10. Chung et al (2011) identified smear-positive disease, 
extensive disease before treatment, prolonged treatment duration and less radiographic improvement 
after treatment as positive risk factors for the deterioration of lung function after treatment61. In the large 
population based studies (PREPCOL, PLATINO and BOLD Cape Town South Africa), a mainly ‘self-
reported’ history of PTB was positively associated with the development of COPD. However, these 
studies fail to expose the dynamic progression of the pathology after treatment. The systematic review 
by Allwood et al (2013) however, confirms the association between a history of PTB and airflow 
obstruction, but whether PTB should be added to the list of recognized exposures for the future 
development of COPD is unclear43. Larger studies measuring the lung function of confirmed PTB 
patients followed up to 18 months after treatment will provide the evidence to confirm the causal nature 
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between PTB and airflow obstruction. However, the results of this study do not differ from smaller 
studies done on similar populations43.  
4.3 Tuberculosis and its impact on Exercise Capacity 
The six-minute walk test (6MWT) is a valid, reliable, safe and cost-effective test to measure exercise 
capacity in COPD patients49. The 6MWT is also a widely-used and validated test of exercise capacity 
for cardiac and pulmonary disorders which could be used as a predictor of morbidity and mortality62. 
Health professionals may opt for the 6MWT above other exercise tests due to its close resemblance of 
activities of daily living, its simplicity and its broad applicability to a wide variety of patient groups57. 
Physiotherapy practices in the primary care setting often have to decrease the course length distance of 
the 6MWT due to limited available space and therefore opt to perform the test over 10m instead57.  
The mean walking distance achieved in this study was 294.5m±122.7m. Due to space limitations at the 
clinics, the authors of this study had to reduce the course length, as measured at the clinics, to 20m. 
When engaging patients at their homes, the course length had to further be reduced to 10m as the 
properties of the homes were small. The impact of PTB on exercise capacity could therefore not be 
established in this population as reference values for the 6MWT are calculated using a distance of 30m 
or more57. However, the distance walked in the present study is comparable to other studies utilizing a 
30m course length in a similar population. Previous studies recorded ranges that varied from 245m to 
415m in PTB populations17,31-33,35. These distances are still well below the distance achieved by healthy 
individuals56  
The 6MWT is often used as an outcome measure for pulmonary rehabilitation programs and has been 
well established in COPD and cardiac rehabilitation programs. There have been very few studies 
evaluating the impact of pulmonary rehabilitation programs on patients with tuberculosis63.  Exercise 
training is an important part of pulmonary rehabilitation and has shown to improve activities of daily 
living and quality of life scores in patients with COPD63. It is generally believed that pulmonary 
rehabilitation can be beneficial in a variety of non-COPD lung disorders including cystic fibrosis, 
pulmonary fibrosis and restrictive thoracic disease35. A study by Ando et al (2003) compared a group of 
post-tuberculosis patients who had undergone thoracoplasty and presented with stable restrictive or 
mixed lung function patterns, with a group of stable COPD patients after a nine week pulmonary 
rehabilitation program using the 6MWT as a comparable outcome measure35. The authors of that study 
found that firstly, the degree of disability between groups are comparable if the FEV1 is the same. 
Secondly, both groups benefitted from a nine week pulmonary rehabilitation program35. The six-minute 
walk distance (6MWD) had improved similarly in both groups and was maintained for up to six months 
after the program35. Another study by Yoshida et al (2006) evaluated the short-term effects of exercise 
training to improve exercise performance in patients with tuberculosis sequelae presenting with a higher 
proportion of restrictive ventilator deficit than obstructive deficit34. The authors found a 10% 
improvement in 6MWD after exercise training. Exercise training using the 6MWT as a comparable 
outcome was considered safe and effective in both of the above studies.  
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 4.4 Challenges of Research in the Rural Setting  
4.4.1 The Community 
Worcester is a small town with a population of approximately 317 3732. It serves as a central hub for 
the Breede Valley District. The district extends from Rawsonville to Touws River, covering a distance 
of approximately 100km between the towns. Most of the surrounding area is privately-owned farmland. 
The majority of the population included in this study classified themselves as coloured, and if employed, 
worked on the farms. Many of the farmers in the district made use of migrant labourers who are 
employed during the harvesting season of the year. The area of De Doorns was plagued by violent 
protests during the start of the data collection period of the current study and the researchers were unable 
to access this community during the protests. The researchers could also only access certain local 
communities in the Worcester region between Tuesdays and Thursdays and between the times of 8am 
and 2pm. These areas were deemed as unsafe to access any other times. 
4.4.2 The Clinics 
The five included clinics in this study each service a dedicated area between Rawsonville and Touws 
River. Patients have access to a clinic depending on their residential location. Worcester CHC is the 
largest clinic in the district and generally handles the TB caseload of the town and its surrounding 
communities. TB patients are initially assessed at the clinic but receive their medication via DOTS 
provided by community workers. Most of the clinics in the district make use of volunteer community 
workers to provide care for the chronically ill who struggle to access the clinics. Community workers 
therefore monitor DOTS patients but are also responsible for patients with other chronic illness such as 
polio, diabetes and strokes. The clinics do not have an electronic database for TB diagnosis and 
monitoring in place. TB nurses therefore have to record all patient data manually in a TB register. At 
majority of the clinics, the researchers could not be accommodated inside the clinic due to limited space 
available. Data collection had to therefore be done outside. 
 
 
Figure 4.1: Spirometry and 6MWT at Rawsonville and Touws River Clinics 
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4.4.3 The Reliability of Patients 
The researchers’ initial plan was to recruit patients at their five month sputum follow-up appointments 
at the clinics. The researchers soon discovered that patients were not given a specific time and date for 
their follow-up appointments but rather a week within which they had to return for their sputum 
appointment. This made it difficult for the researchers to know when to be at which clinic. In the more 
rural areas, patients had to occasionally walk up to 30km to the nearest clinic. TB nurses at the larger 
clinics also struggle to communicate with patients as their contact details are seldom accurate. The TB 
nurses therefore send letters with community workers informing patients of an overdue appointment. 
4.4.4 The BOLD Core Questionnaire 
The BOLD Core questionnaire is a questionnaire that was created mostly from existing, validated 
questionnaires47. The questionnaire has been validated in multi-national studies utilizing the BOLD 
methodology. It is intended to collect data on respiratory symptoms, exposure to risk factors, occupation, 
co-morbidities, health care utilization, activity limitations and health status47. Even though the 
questionnaire has been translated into Afrikaans and validated in the Uitsig community in Cape Town, 
patients in this population seemed to struggle understanding the level of questioning in the questionnaire. 
Patients from the more rural areas who generally had a lower level of education took much longer to 
complete the questionnaire than those with a higher level of education. It appeared to researchers that 
patients would answer the questions whether they understood the questions or not. On average, the 
questionnaire took between 30 and 40 minutes to complete. The questionnaire did not seem patient 
friendly for the study population. Allowing patients to speak freely about their experiences after PTB 
treatment rather than provide them with a set of preset answers may have resulted in more reliable 
responses in the present population. 
4.5 Limitations to the Study 
This study presented with a few limiting factors which may have influenced the validity of the results. 
External validity was mainly affected by population validity. Firstly, the small sample size means that 
the results cannot be generalized for the current population.  Personological factors, such as patients not 
truly understanding the motivation behind why they were being subjected to the tests, as well as patients’ 
poor perceptions of their health status may have impacted on their motivation to perform tests. The 
questionnaire used in the study presented patients with multiple choice options. This could have affected 
the measurement of the dependant variables of the questionnaire when compared to allowing patients to 
speak freely about their perceptions of the disease. Challenges (such as space limitations and 
environmental factors that were not ideal for data collection) may have impacted on the quality of 
measurement of outcome measures. The time period for data collection was limited and this had a huge 
impact on sample size and therefore generalizability of the results. Gaining permission from the local 
farmers to access the farms will ensure patients are present for data collection as for many patients, the 
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more time they spend away from work the less they are paid. Improved patient preparation and an 
explicit explanation of the study procedure will help patients better understand the reasons for the 
research and may improve patient motivation. 
4.6 Recommendations for future research and Clinical Relevance 
The information gathered in this pilot study should be used to inform researchers interested in executing 
larger observational studies in the Overberg region. 
 Recruitment Strategies: To ensure a larger population, future researchers should understand the 
barriers associated with patient recruitment in the Overberg region. Despite planning and good 
communication with the PHCF managers of the included clinics, issues such as migrant labour, 
violence and patients unable to attend the clinics were major barriers. Each clinic in the present 
study had a different means of communicating with the patients and the researchers had to adapt 
and develop patient recruitment strategies for each clinic. Possibly including the farmers in the 
planning of future studies and intercepting patients at their place of work could ensure a more 
compliant patient sample as patients are paid for hours worked and missing work to attend 
clinics would mean less income. 
 The 6MWD: The 6MWD had to be reduced to accommodate lack of space at the clinics and the 
small living area with rough rocky terrain and steep gradients at patients’ homes. This is a 
common occurrence in rural research around the world57. Despite the modifications to the 
6MWT in the present study, distances achieved were comparable to other studies executing the 
6MWT in a similar population. The variability in the 6MWT distances achieved in the literature 
and modifications to accommodate lack of space in the rural setting means that established 
reference values and indicators for mobidity and mortality should not be used in this population. 
Researchers should consider the impact of these modifications and establish normal reference 
values for a reduced 6MWT distance and possibly include measurements of maximal oxygen 
consumption (VO2max) as an indicator of sub-maximal aerobic exercise capacity. The 2 minute 
walk test should also be considered as a viable alternative to the 6MWT in the community 
setting. 
 The BOLD Core Questionnaire: While the questionnaire has been previously validated in a 
COPD population in the Cape Metropole of the Western Cape, the PI is of the opinion that some 
sections of the questionnaire may have been difficult for patients in the more rural farmlands to 
answer. Some patients took much longer to respond to questions than others. Stigmas associated 
with TB in the community may have also played a role in the way patients responded to 
questions, despite the fact that all patients were interviewed privately. The SF-12v2, however, 
was sensitive enough to reveal patients perceptions of their physical and mental health status, 
which were comparable to health perceptions in other PTB populations.      
 Researchers should consider establishing reliable reference data values for a decreased course 
length in the 6MWT. This will aid in more reliable assessment of exercise capacity in this 
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study population. The 2 minute walk test should also be considered as an alternative to the 
6MWT in the community where patient compliance and completion rates of the 6MWT are 
poor. 
 Albeit that the researchers developed specific recruitment strategies for each of the included 
PHCF’s, only a small number of patients were recruited. Future studies should further develop 
these strategies to optimize patient recruitment. 
 The inclusion of a control group of normal people from the same region may provide future 
researchers with a baseline for comparison of HRQoL in the region.  
 The authors suggest that cured PTB patients  be monitored for up to 18 months after they have 
completed PTB treatment to establish whether there is progression of the pathology with 
relation to spirometry, HRQoL and exercise capacity  
4.7 Conclusion 
The findings of this observational study suggest that even after microbiological cure, PTB patients suffer 
from a decreased quality of life, impaired lung function and possibly, a decreased functional exercise 
capacity. Policies addressing a bio-psycho-social model should be implemented at primary care level 
which includes a holistic management of PTB patients, even after they have been deemed 
microbiologically cured. Physiotherapists at primary care institutions should continue monitoring 
patients after anti-TB treatment and consider including these patients in a regular pulmonary 
rehabilitation program as early as possible. This may have a positive impact on a patient’s quality of life 
while simultaneously improving/maintaining the patient’s lung function. This was a pilot study aimed 
at describing the functional health status and quality of life of a cured PTB population in the Breede 
Valley sub-distrct of the Overberg region in the Western Cape. The information gained and recruitement 
strategies developed in this pilot study is intended to inform the planning and development of a larger 
observational study in the region. 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 64 | P a g e  
 
References: 
1. Hubert Lam K, Jiang C, Jordan R, et al. Prior TB, smoking, and airflow obstruction: A cross-
sectional analysis of the guangzhou biobank cohort study. Chest. 2010;137(3):593. 
2. Western cape 2011/2012 annual performance plan. 
http://www.westerncape.gov.za/other/2011/3/health app 2011 2012.pdf2012. 
3. Poh S. Airway obstruction in patients with treated pulmonary tuberculosis. Singapore Medical 
Journal. 1975;16(1):43. 
4. Ehrlich R, Jithoo A. Chronic respiratory diseases in south africa. . March 2011:122. 
5. Snider G, Doctor L, Demas T, Shae A. Obstructive airway disease in patients with treated 
pulmonary tuberculosis. American Review of Respiratory Disease. 1971;103:625. 
6. Chakrabarti B, Calverley P, Davies P. Tuberculosis and its incidence, special nature and 
relationship with chronic obstructive pulmonary disease. international Journal of COPD. 
2007;2(3):263. 
7. Elkington P, Friedland J. Matrix metalloproteinases in destructive pulmonary pathology. Thorax. 
2006;61:259. 
8. Aggarwal A, Gupta D, Janmeja A, Jindal S. Assessment of health-related quality of life in patients 
with pulmonary tuberculosis under programme conditions. International Journal of Tuberculosis and 
Lung Disease. 2013;17(7):947. 
9. Ehrilich R, Adams S, Baatjies R, Jeebhay M. Chronic airflow obstruction and respiratory symptoms 
following tuberculosis: A review of south african studies. The International Journal of Tuberculosis 
and Lung Disease. 2011;15(7):886. 
10. Hnizdo E, Singh T, Churchyard G. Chronic pulmonary function impairment caused by initial and 
recurrent pulmonary tuberculosis following treatment. Thorax. 2000;55(1):32. 
Stellenbosch University  https://scholar.sun.ac.za
 65 | P a g e  
 
11. Eisner M, Blanc P, Yelin E, et al. Influence of anxiety on health outcomes in COPD. Thorax. 
2010;65:229. 
12. Leung A. Pulmonary tuberculosis: The essentials. Radiology. 1999;210:307. 
13. Boland/overberg region annual health status report 2007/2008. 
http://www.westerncape.gov.za/Text/2009/12/boland_overberg_region_07_08.pdf2012. 
14. Wood R, Liang H, Wu H, et al. Changing prevalence of tuberculosis infection with increasing age 
in high-burden townships in south africa. International Journal of Tuberculosis and Lung Disease. 
2010;14(4):406. 
15. Arskey H, O'Malley L. Scoping studies: Towards a methodological framework. International 
Journal of Social Research Methodology. 2005;8(1):19. 
16. Awaisu A, Haniki NM, Noordin N, et al. Impact of connecting tuberculosis directly observed 
therapy short-course with smoking cessation on health-related quality of life. Tobacco Induced 
Diseases. 2012;10(1):2. 
17. Godoy MD, Marcos DP, Mello, et al. The functional assessment of patients with pulmonary 
multidrug-resistant  Tuberculosis. Respiratory Care. 2012;Vol 57(No 11):1949. 
18. Babikako H, Neuhauser D, Katamba A, Mupere E. Feasibility, reliability and validity of health-
related quality of life questionnaire among adult pulmonary tuberculosis patients in urban uganda: 
Cross-sectional study. Health and Quality of Life Outcomes. 2010;8(1):93. 
19. Marra C, Marra F, Colley L, Moadebi S, Elwood R, Fitzgerald J. Health related quality of life 
trajectories amoung adults with tuberculosis - differences between latent and active infection. Chest. 
2008;133:396. 
20. Pasipanodya J, Vecino E, Miller T, et al. Using the st george respiratory questionnaire to ascertain 
health quality in persons with treated pulmonary tuberculosis. Chest. 2007;132(5):1591. 
Stellenbosch University  https://scholar.sun.ac.za
 66 | P a g e  
 
21. Kruijshaar ME, Lipman M, Essink-Bot M-, et al. Health status of UK patients with active 
tuberculosis. International Journal of Lung Disease. 2010;14(3):296. 
22. Atif MS, S. A. S. Shafie, A. A. Muttalif, A. R. Hassali, M. A. Saleem F. Health-related quality of 
life (HRQoL) in co-morbid tuberculosis relapse patient: A case report from malaysia. Tropical Journal 
of Pharmaceutical Research. 2012;11(4):651. 
23. Chamla D. The assessment of patients' health-related quality of life during tuberculosis treatment 
in wuhan, china. International journal of Tuberculosis and Lung Disease. 2004;8(9):1100. 
24. Lemos, Larissa de Araujo F, Alexsandra RG, Elucir Gimeniz Galvao, Marli Teresinha. Quality of 
life aspects of patients with HIV/tuberculosis co-infection. Acta Paulista De Enfermagem. 
2012;25(1):41. 
25. Othman GQ, Ibahim MIM, Raja'a YA. Health related quality of life of pulmonary and 
extrapulmonary tuberculosis patients in yemen. African Journal of Pharmacy and Pharmacology. 
2011;5(4):547. 
26. Deribew A, Tesfaye M, Hailmichael Y, et al. Tuberculosis and HIV co-infection: Its impact on 
quality of life. Health and Quality of Life Outcomes. 2009;7(1):105. 
27. Dhingra V, Rajpal S. Health related quality of life (HRQOL) scoring in tuberculosis. Indian 
Journal of Tuberculosis. 2003(50):99. 
28. Guo N, Marra F, Marra C. Measuring health-related quality of life in tuberculosis: A systematic 
review. Health and Quality of Life Outcomes. 2009;7(1):14. 
29. Santana M, Feeney D. The importance of measuring health related quality of life. IHE Report. 
2008. 
30. Cramm J, Finkenflugel H, Moller V, Nieboer A. TB treatment initiation and adhearence in a south 
african community influenced more by perceptions than by knowlegde of tuberculosis. BMC Public 
Health. 2010;10(72). 
Stellenbosch University  https://scholar.sun.ac.za
 67 | P a g e  
 
31. Maguire G, Anstey N, Ardiand M, et al. Pulmonary tuberculosis, impaired lung function, disability 
and quality of life in a high-burden setting. International Journal of Tuberculosis and Lung Disease. 
2009;13(12):1500. 
32. Pontororing G, Kenangalem E, Lolong D, et al. The burden and treatment of HIV in tuberculosis 
patients in papua province, indonesia: A prospective observational study. BMC Infectious Diseases. 
2010;10(1):362. 
33. Sivaranjini S, Vanamail P, Eason J. Six minute walk test in people with tuberculosis sequelae. 
Cardiopulmonary Physical Therapy Journal. 2010;21(3):5. 
34. Yoshida N, Yoshiyama T, Asai E, Komatsu Y, Sugiyama Y, Mineta Y. Exercise training for the 
improvement of exercise performance of patients with pulmonary tuberculosis sequelae. Internal 
Medicine. 2006;45(6):399. 
35. Ando M, Mori A, Esaki H, et al. The effect of pulmonary rehabilitation in patients with post-
tuberculosis lung disorder. Chest. 2003;123(6):1988. 
36. Pasipanodya J, Vecino E, Miller T, et al. Non-hispanic whites have higher risk for pulmonary 
impairment from pulmonary tuberculosis. BMC Public Health. 2012;12(1):119. 
37. Menezes A, Hallal P, Perez-Padilla R, et al. Tuberculosis and airflow obstruction: Evidence from 
the PLATINO study in latin america. European Respiratory Journal. 2007;30:1180. 
38. Candela A, Andujar J, Hernandes L, et al. Functional sequelae of tuberculosis pleurisy in patients 
correctly treated. Chest. 2003;123(6):1996. 
39. Long R, Maycher B, Dhar A, Manfreda J, Hershfield E, Anthonisen N. Pulmonary tuberculosis 
treated with directly observed therapy: Serial changes in lung structure and function. Chest. 
1998;113(4):993. 
40. de Valliere S, Barker R. Residual lung damage after completion of treatment for multidrug-
resistant tuberculosis. International Journal of Tuberculosis and Lung Disease. 2004;8(6):767. 
Stellenbosch University  https://scholar.sun.ac.za
 68 | P a g e  
 
41. Lee S, Kim Y, Kim D, Oh Y, Lee SD. The risk of obstructive lung disease by previous pulmonary 
tuberculosis in a country with intermediate burden of tuberculosis. Journal of Korean Medical 
Sciences. 2011;26:268. 
42. Baig I, Saeed W, Khalil K. Post-tuberculous chronic obstructive pulmonary disease. Journal of the 
College of Physicians and Surgeons. 2010;20(8):542. 
43. Allwood B, Bateman E, Myer L. A systematic review of the association between pulmonary 
tuberculosis and the development of chronic airflow obstruction in adults. Respiration. 2013;86:76. 
44. van Zyl Smit R, Pai M, Yew W, et al. Global lung health: The colliding epidemics of tuberculosis, 
tobacco smoking, HIV and COPD. European Respiratory Journal. 2010;35(1):27. 
45. Lulloo U, Abraham A. Not all COPD is caused by cigarette smoking. Continuing Medical 
Education. 2009;27(4):170. 
46. WHO. Preamble to the constitution of the world health organisation as adopted by the international 
health conference, new york, 19-22 june 1964, and entered into force on 7 april 1948. .  
47. Buist A, Vollmer M, McBurnie A. Worldwide burden of COPD in high- and low-income 
countries.part I.the burden of obstructive lung disease (BOLD) initiative. The International Journal of 
Tuberculosis and Lung Disease. 2008;12(7):703. 
48. ATS: Standardization of spirometry. European Respiratory Journal. 2005;26:319. 
49. ATS statement: Guidelines for the six minute walk test. American Journal of Respiratory and 
Critical Care Medicine. 2002;166:111. 
50. Mohammad Y, Shaaban R, Al-Zahab B, Khaltaev N, Bousquet J, Dubaybo B. Impact of active and 
passive smoking as risk factors for asthma and COPD in woman presenting to primary care in 
syria:First report by the WHO-GARD survey group. international Journal of COPD. 2013;8:473. 
Stellenbosch University  https://scholar.sun.ac.za
 69 | P a g e  
 
51. Liistro G, Vanwelde C, Vincken W, Vandevoorde J, Verleeden G, Buffels J. Techmical and 
functional assessment of 10 office spirometers: A multicenter comparitive study. Chest. 2006;130:657. 
52. Andersen A, Vinther A, Poulsen L, Mellemgaard A. Do patients with lung cancer benefit from 
physical exercise. Acta Oncologica. 2011;50:307. 
53. Degryse J, Buffels J, Van Dijck Y, Decramer M, Nemery B. Accuracy of office spirometry 
performed by primary-care physicians using the MIR spirobank hand-held spirometer. Respiration. 
2012;83:543. 
54. Ware J, E.Jr., Bayliss M, Rogers W, Kosinski M, Tarlov A. Differences in 4-year health outcomes 
for elderly and poor, chronically ill patients treated in HMO and free-for-service systems. results from 
the medical outcomes study. Journal of American Medical Association. 1996;276(13):1039. 
55. Plit M, Andersen R, Van Rensberg C, Page-Shipp L, Blott J, Frensen J. Influence of antimicrobial 
chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary 
tuberculosis. European Respiratory Journal. 1998;12:351. 
56. Casanova C, Chelli BR, Barria P, et al. The 6-min walk distance in healthy subjects: Reference 
standards from seven countries. European Respiratory Journal. 2011;37(1):150. 
57. Beekman E, Mesters I, Hendriks E, et al. Course length of 30m versus 10m has a significant 
influence on 6 minute walk distance in patients with COPD: An experimental cross over study. 
Journal of Physiotherapy. 2013;59:169. 
58. Bohnannon R, Beubela D, Magasi S, et al. Comparison of walking performance over the first 2 
minutes and the full 6 minutes of the six-minute walk test. BMC Research Notes. 2014;7:269. 
59. Louw J, Peltzer K, Naidoo P, Matseke G, Mchunu G, Tutshana B. Quality of life among 
tuberculosis (TB), TB retreatment and/or TB-HIV co-infected primary public health care patients in 
three districts in south africa. Health and Quality of Life Outcomes. 2012;10(1):77. 
Stellenbosch University  https://scholar.sun.ac.za
 70 | P a g e  
 
60. Guo N, Marra F, Marra C. Measuring health-related quality of life in tuberculosis: A systematic 
review. Health and Quality of Life Outcomes. 2009;7(1):14. 
61. Chung K, Chen J, Lee C, et al. Trends and predictors of change in pulmonary function after 
treatment for tuberculosis. Clinics. 2011;66(4):549. 
62. Enright P, Kaminsky D. Strategies for screening for chronic obstructive pulmonary disease. 
Respiratory Care. 2003;8(12):1194. 
63. Horie J, Itou K, Fuji H, Ishihara H, Horikawa E. Exercise limitation factors of patients with 
chronic respiratory failure: A comparison of chronic obstructive pulmonary disease and sequelae of 
pulmoanry tuberculosis. Journal of Physical Therapy Science. 2009;21:155. 
  
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 71 | P a g e  
 
Appendix A-1: Permission to gain access to the clinics and to use the BOLD Core Questionnaire 
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Appendix A-2: Consent Form English 
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
TITLE OF THE RESEARCH PROJECT: 
An Investigation into the lung function, health related quality of life (HRQoL) and functional capacity 
of a cured Pulmonary Tuberculosis (PTB) population in the Breede Valley: a pilot study 
PREFERENCE NUMBER:  
PRINCIPAL INVESTIGATOR: Mr K.J. Daniels 
ADDRESS: 30 The Vines West 
  Steenbok Street 
  Durbanville  
  Cape Town 
CONTACT NUMBER: 0844477490 
You are being invited to take part in a research project.  Please take some time to read the information 
presented here, which will explain the details of this project.  Please ask the study staff or doctor any 
questions about any part of this project that you do not fully understand.  It is very important that you 
are fully satisfied that you clearly understand what this research entails and how you could be 
involved.  Also, your participation is entirely voluntary and you are free to decline to participate.  If 
you say no, this will not affect you negatively in any way whatsoever.  You are also free to withdraw 
from the study at any point, even if you do agree to take part. 
This study has been approved by the Committee for Human Research at Stellenbosch University and 
will be conducted according to the ethical guidelines and principles of the international Declaration of 
Helsinki, South African Guidelines for Good Clinical Practice and the Medical Research Council 
(MRC) Ethical Guidelines for Research. 
What is this research study all about? 
The aim of this study is to try and identify problems that you might have in your everyday life after 
you have completed your TB treatment. TB does damage to the lung tissue and therefore could affect 
your breathing, work or the way that you do your everyday activities. Participants for this study are 
selected based on the local clinics database of patients who have been on  TB treatment. Participants 
who test negative for TB at their 5 month clinic visit will be asked to participate in this study. 
Participants will be asked to complete a questionnaire about their breathing, daily activities and 
lifestyle. They will then be asked to perform lung function tests which will be done by a trained 
professional. Lastly, they will be asked to participate in a test designed to assess how tired they get 
while doing normal activities. 
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Why have you been invited to participate? 
Participants have been specifically invited to participate in this study because you have been 
diagnosed with TB, and are currently completing your TB treatment at your local clinic.  
What will your responsibilities be? 
As a participant in the study, you will be expected to complete a questionnaire, perform a test to assess 
how well your lungs work and perform a test to assess how tired you get while doing everyday 
activities. 
Will you benefit from taking part in this research? 
You do not stand to gain any financial benefit from the research. The results of this study will benefit 
patients in the future and help us identify how to effectively manage patients after they have 
completed their TB treatment. 
Are there any risks involved in your taking part in this research? 
The study procedures are designed to have minimal risks. Participants are advised to discontinue the 
tests if they feel heart or chest pains, severe shortness of breath, severe headaches and dizziness. 
As a participant, will be expected to perform measurements to see how well your lungs work 20 
minutes after the administration of a short acting bronchodilator (medication to help you breathe 
easier). Fainting in older people and participants with weak lungs are the primary risks associated with 
the manoeuvre. Tremors and an increase in heart rate are adverse effects associated with 
bronchodilator usage. (medication) 
If you do not agree to take part, what alternatives do you have? 
This study serves as a baseline study for future implementation. If you do not wish to participate, the 
management of your condition will continue as per normal. 
Who will have access to your medical records? 
All information gathered and used in the study will be treated as strictly confidential and protected. If 
the study is used in publications, the identity of the participant will remain anonymous. Only doctors, 
the researcher and specifically appointed research assistants will have access to the information.  
Will you be paid to take part in this study and are there any costs involved? 
No, you will not be paid to take part in the study.  There will be no costs involved for you, if you 
do take part. Your study appointments will coincide with your normal clinic appointment. 
Is there anything else that you should know or do? 
You should inform your family practitioner or usual doctor that you are taking part in a 
research study.   
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You can contact Mr Kurt Daniels at tel. 0844477490 if you have any further queries or 
encounter any problems. 
You can contact the Committee for Human Research at 021-938 9207 if you have any concerns 
or complaints that have not been adequately addressed by your study doctor. 
You will receive a copy of this information and consent form for your own records. 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in an inspiratory 
muscle training program research study entitled  An Investigation into the lung function, health related 
quality of life (HRQoL) and functional capacity of a cured Pulmonary Tuberculosis (PTB) population 
in the Breede Valley: a pilot study 
I declare that: 
 
I have read or had read to me this information and consent form and it is written in a language with 
which I am fluent and comfortable. 
I have had a chance to ask questions and all my questions have been adequately answered. 
I understand that taking part in this study is voluntary and I have not been pressurised to take part. 
I may choose to leave the study at any time and will not be penalised or prejudiced in any way. 
I may be asked to leave the study before it has finished, if the study doctor or researcher feels it is in 
my best interests, or if I do not follow the study plan, as agreed to. 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2012 
Signature of participant Signature of witness 
Declaration by investigator 
I (name) ……………………………………………..……… declare that: 
I explained the information in this document to ………………………………….. 
I encouraged him/her to ask questions and took adequate time to answer them. 
I am satisfied that he/she adequately understands all aspects of the research, as discussed above 
I did/did not use a translator.  (If a translator is used then the translator must sign the declaration 
below. 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2012 
Signature of investigator Signature of witness 
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Declaration by translator 
I (name) ……………………………………………..……… declare that: 
I assisted the investigator (name) ………………………………………. to explain the information in 
this document to (name of participant) ……………..…………………………….. using the language 
medium of Afrikaans/Xhosa. 
We encouraged him/her to ask questions and took adequate time to answer them. 
I conveyed a factually correct version of what was related to me. 
I am satisfied that the participant fully understands the content of this informed consent document and 
has had all his/her question satisfactorily answered. 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2012 
    
Signature of translator Signature of witness 
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Appendix A-3: Consent Form Afrikaans 
DEELNEMERINLIGTINGSBLAD EN -TOESTEMMINGSVORM 
TITEL VAN DIE NAVORSINGSPROJEK: 
An Investigation into the lung function, health related quality of life (HRQoL) and functional capacity 
of a cured Pulmonary Tuberculosis (PTB) population in the Breede Valley: a pilot study 
VERWYSINGSNOMMER: 
HOOFNAVORSER: : Mr K.J. Daniels 
ADRES: 30 The Vines West 
  Steenbok Street 
  Durbanville  
  Cape Town 
KONTAKNOMMER: 0844477490 
U word genooi om deel te neem aan ’n navorsingsprojek.  Lees asseblief hierdie inligtingsblad op u tyd 
deur aangesien die detail van die navorsingsprojek daarin verduidelik word.  Indien daar enige deel van 
die navorsingsprojek is wat u nie ten volle verstaan nie, is u welkom om die navorsingspersoneel of 
dokter daaroor uit te vra.  Dit is baie belangrik dat u ten volle moet verstaan wat die navorsingsprojek 
behels en hoe u daarby betrokke kan wees.  U deelname is ook volkome vrywillig en dit staan u vry om 
deelname te weier.  U sal op geen wyse hoegenaamd negatief beïnvloed word indien u sou weier om 
deel te neem nie.  U mag ook te eniger tyd aan die navorsingsprojek onttrek, selfs al het u ingestem om 
deel te neem. 
Hierdie navorsingsprojek is deur die Komitee vir Mensnavorsing van die Universiteit Stellenbosch 
goedgekeur en sal uitgevoer word volgens die etiese riglyne en beginsels van die Internasionale 
Verklaring van Helsinki en die Etiese Riglyne vir Navorsing van die Mediese Navorsingsraad (MNR). 
Wat behels hierdie navorsingsprojek? 
Die doel van die studie is om te identifiseer of jy probleme ondervind in jou daaglikse lewe nadat jy die 
TB behandeling voltooi het. TB veroorsaak skade aan die long weefsel en kan gevolglik ‘n invloed he 
op jou asemhaling, werk en self op die wyse waarop jy allerdaagse aktiwiteite uitvoer. Pasiente vir die 
studie word gekies deur databasisse van die klinike in hulle omgewing na te gaan en so te sien watter 
pasiente op die 6 maande TB behandeling was. Pasiente wie wat op TB behandeling was en na 5 maande 
by hulle kliniek besoek negatief toets, sal gevra word om aan die studie deel te neem. Wanneer die 
pasiente dan terug keer na die kliniek vir hulle finale besoek op 6 maande, sal hulle dan gevra word om 
‘n vraelys in te vul oor hulle asemhaling, daaglikse aktiwiteite en leefstyl. Daarna sal gevra word dat 
hulle ‘n longfunksie toets ondergaan, die toets sal deur ‘n proffesionele person toegepas word. Laastens 
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sal hulle ook gevra word om deel te neem aan ‘n toets wat spesifiek ontwerp is om te waar te neem hoe 
moeg die pasient raak terwyl hulle nomale aktiwiteite uit voer.  
Waarom is u genooi om deel te neem? 
U word spesifiek uitgenooi om deel te neem aan die studie aangesien u gediagnoseer was met TB en 
tans u TB behandeling by u naaste kliniek voltooi. 
Wat sal u verantwoordelikhede wees? 
As ‘n deelnemer in die studies sal daal van u verwag word om ‘n vraelys in te vul; ‘n longfunksie toets 
te ondergaan en ‘n toets te doen om sodoende u funksionele kapasiteit te bepaal. 
Sal u voordeel trek deur deel te neem aan hierdie navorsingsprojek? 
Deelnemers sal geen finansiele vergoeding ontvang vir die navorsing nie. Die uitslag van die studies sal 
al die deelnemers in die toekoms tot voordeel staan, dit sal ons help om pasiente meer effektief te 
behandel nadat hulle, hul TB behandeling voltooi het. 
Is daar enige risiko's verbonde aan u deelname aan hierdie navorsingsprojek? 
Die studie is ontwerp om minimale risiko’s te dra. Deelnemer word aanbeveel om dadelik met die toetse 
te stop indien hulle enige hart, borskaspyn, kortased, erge kopseer of duisligheid ervaar.  
Watter alternatiewe is daar indien u nie instem om deel te neem nie? 
Die studie dien as a basis studie vir verdere implimentasie. Indien u sou besluit om nie aan die studie 
deel te neem nie sal u TB behandeling soos normal voortgaan. 
Wie sal toegang hê tot u mediese rekords? 
Al die versamelde inligting sal vertroulik en beskermd gehanteer word. Die deelnemer sal anoniem bly 
indien die resultate gebruik work vir ‘n publikasie of tesis. Net die dokters en narvorsings personeel sal 
toegang tot die inligting he. 
Sal u betaal word vir deelname aan die navorsingsprojek en is daar enige koste verbonde aan deelname? 
 
U sal nie betaal word vir deelname aan die navorsingsprojek nie, maar u vervoer en etes ten opsigte van 
elke besoek vir die navorsingsprojek sal betaal word.  Deelname aan die navorsingsprojek sal u niks kos 
nie. 
 
 
Is daar enigiets anders wat u moet weet of doen? 
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U moet u huisarts of gereelde algemene praktisyn in kennis stel van u deelname aan die 
navorsingsprojek. (sluit in indien van toepassing) 
U moet ook u mediese fonds in kennis stel van u deelname aan die navorsingsprojek. (sluit in indien van 
toepassing) 
U kan Mr Kurt Daniels kontak by tel. 0844477490 indien u enige verdere vrae het of enige probleme 
ondervind. 
U kan die Komitee vir Mensnavorsing kontak by 021-938 9207 indien u enige bekommernis of klagte 
het wat nie bevredigend deur u studiedokter hanteer is nie. 
U sal ’n afskrif van hierdie inligtings- en toestemmingsvorm ontvang vir u eie rekords. 
Verklaring deur deelnemer 
Met die ondertekening van hierdie dokument onderneem ek,  
 
…….....................……….....……...……….., om deel te neem aan ’n navorsingsprojek getiteld An 
Investigation into the lung function, health related quality of life (HRQoL) and functional capacity of a 
cured Pulmonary Tuberculosis (PTB) population in the Breede Valley: a pilot study 
Ek verklaar dat: 
Ek hierdie inligtings- en toestemmingsvorm gelees het of aan my laat voorlees het en dat dit in ’n taal 
geskryf is waarin ek vaardig en gemaklik mee is. 
Ek geleentheid gehad het om vrae te stel en dat al my vrae bevredigend beantwoord is. 
Ek verstaan dat deelname aan hierdie navorsingsprojek vrywillig is en dat daar geen druk op my geplaas 
is om deel te neem nie. 
Ek te eniger tyd aan die navorsingsprojek mag onttrek en dat ek nie op enige wyse daardeur benadeel 
sal word nie. 
Ek gevra mag word om van die navorsingsprojek te onttrek voordat dit afgehandel is indien die 
studiedokter of navorser van oordeel is dat dit in my beste belang is, of indien ek nie die ooreengekome 
navorsingsplan volg nie. 
Geteken te (plek) ..............................…………….. op (datum) …………....……….. 2005.  
Handtekening van deelnemer Handtekening van getuie 
Verklaring deur navorser 
Ek (naam) …………………………………...……………… verklaar dat: 
Ek die inligting in hierdie dokument verduidelik het aan 
…………………….............................................……….. 
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Ek hom/haar aangemoedig het om vrae te vra en voldoende tyd gebruik het om dit te beantwoord. 
Ek tevrede is dat hy/sy al die aspekte van die navorsingsprojek soos hierbo bespreek, voldoende 
verstaan. 
Ek ’n tolk gebruik het/nie ’n tolk gebruik het nie.  (Indien ’n tolk gebruik is, moet die tolk die 
onderstaande verklaring teken.) 
Geteken te (plek) ..............................…………….. op (datum) …………....……….. 2005. 
Handtekening van navorder Handtekening van getuie 
Verklaring deur tolk 
Ek (naam) …………………………………...……………… verklaar dat: 
Ek die navorser (naam) ……….............................…………………. bygestaan het om die inligting in 
hierdie dokument in Afrikaans/Xhosa aan (naam van deelnemer) 
……………………………......................... te verduidelik. 
Ons hom/haar aangemoedig het om vrae te vra en voldoende tyd gebruik het om dit te beantwoord. 
Ek ’n feitelik korrekte weergawe oorgedra het van wat aan my vertel is. 
Ek tevrede is dat die deelnemer die inhoud van hierdie dokument ten volle verstaan en dat al sy/haar 
vrae bevredigend beantwoord is. 
Geteken te (plek) ..............................…………….. op (datum) …………....……….. 2005.  
Handtekening van tolk Handtekening van getuie 
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Appendix A-4: Ethics Approval 
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Appendix B-1: Flow diagram of patient recruitment procedure 
 
Flow Diagram of Recruitment Procedure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The PI visited all of the PHC clinics in the Breede Valley region during the pre data 
collection phase 
 The names of the patients returning for their 5 month sputum test follow up 
appointments were be obtained from the TB registry at each of the various clinics 
 Patients who have completed their sputum test at their 5 month follow up 
appointment were be recruited and to participate in the study 
 Only the data of patients who are deemed “cured” will be submitted for analysis 
Data processing and analysis 
If the patient agrees, they will follow through the 4 stations 
set up by the Primary Investigator, ie: 
BMI  
Health Related Quality of Life questionnaire 
Lung Function Measurements 
6-Minute Walk test 
 
 
 
 
Patients not recruited: 
 Those who decline to 
participate 
 Those not meeting the 
inclusion criteria  
 Those for whom spirometry 
is contraindicated 
Data required: 
Weight and Height 
Measurements 
BOLD core questionnaire 
data 
Spirometry report 
6 minute walk test report 
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Appendix B-2: Recruitment Strategies for individual clinics 
Clinic Patient Recruitment Strategies 
Touws Rivier Clinic 
The researcher would travel to the clinic and set up a date that suited both him and the staff at the 
clinic. On the same day, the researcher would ask the TB nurse for a list of names of patients that have 
either completed, or are going to complete their TB treatment in that month. The nurse would then 
contact the patients and ask them to come through to the clinic on the date that was arranged. 
This strategy worked well as the TB nurse knows the patients personally. She mentioned that she does 
community visits on a Friday and that is when she would convey the information to the patients. The 
only unreliable aspect was the patients themselves. Even though patients confirmed that they would 
come to the clinic on the set date, when the researcher arrived at the clinic, maybe 1 or 2 of the booked 
patients would pitch. 
One way of eliminating the fact that the researcher is reliant on the patients to come to the clinic is 
possibly setting up a date when the research team could accompany the nurse on the home visits and 
recruit the patients at their home. My only concern with this is that the homes may not have the 
capacity to accommodate the 6MWT. 
Orchards Clinic 
Orchards clinic is a tiny clinic that mainly services the surrounding farming area. At this clinic, the 
researcher would once again set up an appointment date with clinic that suited everyone. The 
researcher would request a list of names of all the patients who have completed or who are completing 
their treatment in the month from the nursing. The nurse knows her patients well and would contact 
the patients (usually when they came to the clinic for their tablets) and ask the patients to report to the 
clinic on the arranged date.  
This worked well as the clinic is small and does not have many TB patients. Due to the personal 
relationship and sense of community amongst the patients, as well as the clinic, patients tend to respect 
and respond to the Dr’s and Nurses at the clinic. All of the patients that were requested or booked 
pitched up for their appointments. 
The patient numbers at the clinic are small and the strategy at this clinic seems to work fine. The 
patients live on farms and there is no way of getting hold of them as most of them do not have contact 
numbers. So, the nurse relies on the patients to come to the clinic for any form of communication, 
because following up on these patients is a definite problem at the clinic. 
De Doorns Clinic 
De Doorns Clinic is a rather large clinic servicing the De Doorns area. Here too, the researcher would 
set up an appointment with the TB nurse for a date that would suit him when the research team could 
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return. The researcher was told that patients were booked at the clinic every day. The number of 
patients that are seen at the clinic per day is unknown. When arriving at the clinic for data collection, it 
seems that the nurse misunderstood the requirement for the study and recruitment had to be done by 
the research team in the waiting area. 
According to the TB nurse, De Doorns clinic also makes use of community workers to carry out the 
DOTS program. Therefore, it is possible that only the patients who have changed their treatment 
regime as well as patients who have to provide sputum samples are the only patients that actually 
come in to the clinic. 
One way to potentially optimize the amount of patients recruited for the study is to work with the 
community workers from the clinic. The community workers can provide a list of names and contact 
numbers of people who are potentially completing treatment and the research team could contact them 
to ask if they would like to participate in the study. They can then decide if the team will go to the 
people’s houses or get everyone to a central point for data collection. 
Rawsonville Clinic 
The researcher would follow the same procedure as for the previous clinics by arranging a date that 
the team could come in for data collection. The first round of data collection at Rawsonville clinc did 
not yield many patients. The researcher was told by the TB nurse that the DOTS program is carried 
out at the clinic and that there are no community workers working in the area. The nurse keeps good 
track of the patients that either need to provide sputum samples, or that are completing treatment. One 
of the biggest issues at the clinic is that most of the patients there do not have contact numbers. They 
are also mostly farm workers which means that time spent working is more money for them. 
Therefore, the reliability of the patients arriving at the clinic when they are scheduled to arrive cannot 
be guaranteed.  
Therefore, in the first round of data collection, the researcher made an appointment to collect data at 
the clinic when more than 1 person was scheduled to provide 5 month sputum samples. All of the 
patients that were scheduled on that day arrived at the clinic. 
For the second round of data collection, the researcher thought that to optimize the amount of patients 
included in the study, he would go to the clinic and compile a list of names of patients that were 
completing treatment in that month from the patients file. From a list of about 12 names: 2 were under 
age and still at school, 6 did not have contact numbers and 4 had contact numbers. Of the 4 with 
contact numbers, only 3 were reachable. All 3 patients arrived at the clinic on the day that was 
scheduled for data collection. 
Worcester CHC 
Worcester CHC was used as home base for the data collection phase. Here, the researcher would 
communicate with the TB nurse as well as the desk clerk who performed all of the administrative tasks 
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of the TB clinic. The TB nurse said that it was extremely difficult for her to know in advance which 
patients were where in their treatment because of the patient numbers at the clinic. Basically, the 
patient collects his/her folder at the folder counter in the morning and would then report to the TB 
clinic. The patient waits in a waiting area until their name is called by the TB nurse. The nurse then 
looks at the patient file and determines the plan of action for the patient. The researchers thus decided 
to recruit patients in the waiting area and stationed a research assistant there to expain what the project 
is about and identify any patients who were eligible for the study. A drawback of this method of 
recruitment was that patients had to self identify if they matched the specified criteria. Patients were 
screened again once they arrived at the data collection stations. Most of the time, the patients folder 
was being held at pharmacy or by a doctor and many patients did not arrive at the data collection 
stations with their clinical folders. 
The researcher decided that the appointment system would not work at this clinic as eligible patients 
for the study were unpredictable. Therefore, the research team decided to stay at the clinic for a week 
from 8am until 1pm and recruit as many patients as possible.  
This method of recruitment did not yield many patients. Many patients who volunteered for the study 
were defaulters who had to have their drug regimen changed. Others were children and under age. 
The clinic does make use of DOTS community workers. Each area in the Worcester region has 
between 2 and 3 community workers taking care of the chronically ill. One of the suggestions to 
overcome the poor patient numbers at Worcester CHC was to possibly work with the community 
workers and let them identify patients who are completing treatment in a particular month. The 
research team could then recruit all of those patients on one day and in one central area with the 
patients having to come to the clinic. The researcher suggested that the community workers identify 
the patients and hand them a letter, written up by the researcher, explaining the project and containing 
an appointment date when the research team will be collecting the data. Another suggestion to 
overcome the poor patient numbers was to use the TB registry and identify patients who have who 
have started their TB treatment in the last 6 months of 2012. The files of all of the patients for which 
there are final negative sputum results will be pulled. A list will be compiled with the patients contact 
number/details as received from the file. These patients will be contacted and asked to come to the 
clinic on a particular day.  
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Appendix B-3: Spirobank II 
Turbine Yes Please! Why the MIR digital turbine does not require calibration 
13 February 2014 at 18:49 
The MIR range of spirometers use a digital turbine flow meter working on the infrared interruption principle. 
The turbine system is made up of the following elements: 
  
 A turbine tube, made from a special polycarbonate material, which is permeable to infrared light, 
 Two deflectors, one at each end of the tube (entry and exit) made from the same polycarbonate 
material,  which serve to create the "swirl" effect of the air passing through the tube, and 
 A moving part or rotor, consisting of a blade plus a metal axis. 
  
Two sets of infrared transmitters (TX) and receivers (RX) detect the rotation of the rotor within the tube and 
generate digital impulses, the number of these impulses is directly proportional to the velocity of the air 
(inspired or expired) passing through the tube. This velocity is a function of the physical form of the two 
deflectors, and the form of the deflectors cannot change during normal use. 
  
The maximum velocity of the rotor, for flows generated during normal spirometry testing, is around 1000 
revolutions per second. The metal axis is made from a special alloy and it is supported at each end by a 
bearing made from a synthetic saphire. This specification excludes the possibility of modifications in the 
response of the turbine due to wear in the turbine mechanism. 
  
In addition, it is very important to underline that, unlike the other kinds of flow meter such as those based on 
pressure, the measurements made with this mechanical flow meter are NOT influenced in any way by the 
ambiental conditions ie temperature, pressure, humidity and density (or viscosity) of the gas being measured. 
  
Given all of the above, it can be be deduced that in normal conditions and with the flow meter undamaged, 
the measurement depends only and exclusively on the velocity of the air in transit through the turbine tube. 
  
The only way in which the measurement can change would be by the presence of some kind of "foreign 
body" within the turbine tube, such as a hair, thread or sputum. This could create a kind of friction which could 
slow down or even stop the normal rotation of the rotor within the turbine tube. 
  
In order to ensure the absence of such friction, MIR spirometers use a software algorithm which constantly 
analyses the movement of the rotor and within a certain range of very low flow the device gives a feedback 
of an acoustic signal "beep" when the flow is within this range, thus ensuring that the rotor is moving freely 
and without any such friction. 
  
Thanks to this constant acoustic feedback before, during and after every spirometry test,the user is able to 
guarantee the correct functioning of the flow measurement system. Of course, the user is also able to use 
any normal system (pump, calibration syringe etc), to check the correct functioning of the system. 
  
To conclude, it is possible to confirm that providing the turbine is kept clean and free from foreign bodies, 
then the response of the turbine set at the factory cannot be modified and thus the turbine does not require 
calibration. 
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Appendix B-4: BOLD Core Questionnaire Used 
Kode van land:  _____ _____ _____   1 
 
Kode van stad: _____ _____   2 
 
ID:  _____ _____ _____ _____   3 
 
Datum: _____ _____/_____ _____/_____ _____ _____ _____   4-6 
d d m m j j j j 
 
BOLD KERNVRAELYS 
Demografiese besonderhede 
 
1. Wat is die geslag van die deelnemer? Manlik  1 7 
Vroulik  2 
 
2. Wat is u ras?    ___ ___ ___  8 
 
3. Wat is u geboortedatum?  ____ ____/____ ____/____ ____ ____ ____ 9-11 
d d m m j j j j 
 
4. Hoeveel jaar van formele onderwys het u voltooi?  ___ ___ 12 
 
5. Wat is die hoogste vlak van formele onderwys wat u Primêre skool   1 13 
voltooi het? Middelbare skool  2 
Hoërskool  3 
Kollege    4 
Technikon/Universiteit  5 
Geen  6 
Onbekend  7 
 
6. Wat is die hoogste vlak van formele onderwys wat Primêre skool  1 14 
u vader voltooi het? Middelbare skool  2 
Hoërskool  3 
Kollege   4 
Technikon/Universiteit  5 
Geen  6 
Onbekend  7 
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Respiratoriese simptome en siektetoestande 
 
Die vrae het hoofsaaklik betrekking op u bors. Antwoord asseblief ja of nee, indien moontlik. Indien u 
twyfel of u antwoord ja of nee moet wees, sê dan asseblief nee. 
 
Hoes 
 
7. Hoes u gewoonlik sonder dat u verkoue is? Ja  1 15 
Nee  2 
[Indien ja, gaan asseblief voort met vraag 7A; indien nee, spring na vraag 8] 
 
7A.  Is daar maande wanneer u die meeste dae hoes? Ja  1 16 
Nee  2 
[Indien ja, vra beide vraag 7B en 7C; indien nee, spring na vraag 8] 
 
7B. Hoes u vir soveel as drie maande per jaar op die meeste dae?     Ja 
 1 17 
Nee  2 
 
7C.  Hoeveel jaar het u al die hoes?   Minder as 2 jaar  1 18 
2-5 jaar  2 
Meer as 5 jaar  

Slym 
 
8. Hoes u gewoonlik slym op uit u bors, of het u gewoonlik Ja  1 19 
slym op u bors wat moeilik uithoes wanneer u nie  Nee  2 
verkoue is nie? 
 
[Indien ja, gaan voort met vraag 8A; indien nee, spring na vraag 9] 
 
8A.  Is daar maande wanneer u op die meeste dae hierdie slym het? Ja  1 20 
Nee  2 
 
[Indien ja, vra beide vraag 8B en 8C; indien nee, spring na vraag 9] 
 
8B.  Hoes u vir soveel as drie maande elke jaar 
die slym op die meeste dae uit?  Ja  1 21 
Nee  2 
 
8C.  Hoeveel jaar het u reeds die slym ?    Minder as 2 jaar  1 22 
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2-5 jaar  2 
Meer as 5 jaar     3 
 
Hyg/Fluit 
 
9. Het u op enige tydstip die afgelope 12 maande ’n gehyg  Ja  1 23 
of gefluit in u bors gehad?  Nee  2 
 
[Indien ja, vra beide vraag 9A en 9B; indien nee, spring na vraag 10] 
 
9A. In die afgelope 12 maande, het u die gehyg of gefluit net Ja  1 24 
gehad terwyl u verkoue was?  Nee  2 
 
9B.  In die afgelope 12 maande, het u ooit ’n hyg- of fluitaanval Ja  1 25
          gehad wat u kortasem laat voel het?  Nee  2 
Kortasemigheid 
 
10.  Ly u aan ’n toestand anders as kortasemigheid wat maak Ja  1 26 
dat u nie kan loop nie? Nee  2 
 
[Indien ja, beskryf die toestand asseblief in die ruimte hieronder en spring dan na vraag 12. Indien 
nee, gaan direk aan met vraag 11. 
 
Aard van die toestand(e): 
 
11. Het u las van kortasemigheid wanneer u vinnig loop op ’n gelykte, of   Ja  1
 27 
teen ’n effense opdraande uitloop?  Nee  2 
 
[Indien ja, vra vraag 11A tot 11D; indien nee, spring na vraag 12] 
 
11A. Moet u op ’n gelykte stadiger loop as ander mense van  Ja  1 28 
u ouderdom omdat u kortasem raak?  Nee  2 
Nie van toepassing  3 
 
11B. Is dit ooit vir u nodig om eers te gaan staan om u asem terug Ja  1 29 
te kry wanneer u teen u eie pas op ’n gelykte loop?  Nee  2 
Nie van toepassing  3 
 
11C. Moet u ooit eers gaan staan om u asem terug te kry nadat  Ja  1 30 
u op ’n gelykte sowat 100 tree geloop Nee  2 
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het (of na ’n paar minute)? Nie van toepassing  3 
 
11D. Is u te kortasem om uit die huis uit te gaan of uitasem Ja  1 31 
nadat u aan- of uitgetrek het?  Nee  2 
Nie van toepassing  3 
 
12.  Het ’n dokter of ander gesondheidsorgverskaffer al ooit Ja  1 32 
vir u gesê dat u emfiseem het? Nee  2 
 
13.  Het ’n dokter of ander gesondheidsorgverskaffer al ooit vir u gesê Ja 
 1 33 
dat u asma, asmatiese brongitis of allergiese brongitis het?  Nee  2 
 
[Indien ja, vra vraag 13A.  Indien nee, spring na vraag 14] 
 
13A. Het u nog steeds asma, asmatiese brongitis of   Ja  1 34 
allergiese brongitis? Nee  2 
 
14.  Het ’n dokter of ander gesondheidsorgverskaffer al ooit vir u gesê Ja 
 1  35 
dat u chroniese brongitis het?  Nee  2 
 
[Indien ja, vra vraag 14A.  Indien nee, spring na vraag 15] 
 
14A. Het u steeds chroniese brongitis?  Ja  1 36 
Nee  2 
 
15. Het ’n dokter of ander gesondheidsorgverskaffer al ooit vir u gesê Ja  1
 37 
dat u chronies obstruktiewe longsiekte het?   Nee  2 
Bestuur van toestand 
 
Nou gaan ek u vrae vra oor enige medisyne wat u dalk neem om u beter te laat asemhaal. Ek wil graag 
weet van medisyne wat u gereeld neem en van medisyne wat u moontlik net neem om simptome te 
verlig. Ek wil graag hê u moet my vertel van al die medisyne wat u neem, in watter vorm u dit neem, 
en hoe dikwels u dit elke maand neem. 
 
16.  In die afgelope 12 maande, het u enige medikasie geneem vir u asemhaling? Ja 1 38 
Nee 2 
 
16A. Medikasie: 
Naam (nie ingevoeg) 
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16B. Medikasie: 
Kode 
 
___ ___ ___  39 
 
___ ___ ___  44 
 
___ ___ ___  49 
 
___ ___ ___  54 
 
___ ___ ___  59 
 
___ ___ ___  64 
 
___ ___ ___  69 
16C. Formulering Pille                  
1 
Inasemtoestel   
2 
Fynsproeier      
3 
Vloeistof          
4 
Setpil                
5 
Inspuiting         
6 
Ander               
7 
Pille                  1 
Inasemtoestel   2 
Fynsproeier      3 
Vloeistof          4 
Setpil                5 
Inspuiting         6 
Ander               7 
Pille                  1 
Inasemtoestel   2 
Fynsproeier      3 
Vloeistof          4 
Setpil                5 
Inspuiting         6 
Ander               7 
Pille                  
1 
Inasemtoestel   
2 
Fynsproeier      
3 
Vloeistof          
4 
Setpil                
5 
Inspuiting         
6 
Ander               
7 
Pille                  
1 
Inasemtoestel   
2 
Fynsproeier      
3 
Vloeistof          
4 
Setpil                
5 
Inspuiting         
6 
Ander               
7 
Pille              1 
Inasemtoestel   
2 
Fynsproeier   3 
Vloeistof       4 
Setpil             5 
Inspuiting      6 
Ander            7 
Pille              1 
Inasemtoestel   
2 
Fynsproeier  3 
Vloeistof      4 
Setpil            5 
Inspuiting     6 
Ander           7 
16D. Neem u die 
medikasie meeste dae, 
net wanneer u simptome 
het, of beide? 
(Indien ‘meeste dae’, 
vra V16E; indien ‘simptome’, 
vra V16F; indien ‘beide’, vra 
V16E en V16F.) 
Meeste dae  1 
Simptome    2 
Beide           3 
 
Meeste dae  1 
Simptome    2 
Beide           3 
 
 
Meeste dae  1 
Simptome    2 
Beide           3 
 
 
Meeste dae  1 
Simptome    2 
Beide           3 
 
 
Meeste dae  1 
Simptome    2 
Beide           3 
 
Meeste dae  1 
Simptome    2 
Beide           3 
 
Meeste dae  1 
Simptome    2 
Beide           3 
 
 
16E. Wanneer u die 
medikasie neem, hoeveel 
dae per week neem u dit? 
 
_______ dae  42 
 
_______ dae  47 
 
_______ dae   52 
 
_______ dae  57 
 
_______ dae  62 
 
_______ dae  67 
 
_______ dae  72 
16F. Terwyl u die 
medikasie moes neem, 
hoeveel maande uit die 
afgelope 12 maande het u 
dit geneem? 
0-3        1       43 
4-6        2 
7-9        3 
10-12    4 
0-3       1        48 
4-6        2 
7-9        3 
10-12    4 
0-3        1         53 
4-6        2 
7-9        3 
10-12    4 
0-3        1        58 
4-6        2 
7-9        3 
10-12    4 
0-3        1        63 
4-6        2 
7-9        3 
10-12    4 
0-3        1        68 
4-6        2 
7-9        3 
10-12    4 
0-3        1        73 
4-6        2 
7-9        3 
10-12    4 
Indien die deelnemer nie enige medikasie neem om met asemhaling te help nie, spring na vraag 17. 
17. Vertel my asseblief van enige ander produkte wat u neem of dinge wat u doen om u 
asemhaling aan te help waarvan u my nog nie vertel het nie. 
 
Medisyne of aktiwiteit Kode 
 ____ ____ ____  74 
 ____ ____ ____  75 
 ____ ____ ____  76 
 ____ ____ ____  77 
 
18. Het ’n dokter of ander gesondheidsorgverskaffer u al ooit  Ja  1 78 
in ’n toestel laat blaas om die lug in u longe te meet (d.w.s. ’n spirometer  Nee  2 
of belugtingsmeter)? 
 
Stellenbosch University  https://scholar.sun.ac.za
 93 | P a g e  
 
[Indien ja, vra vraag 18A. Indien nee, spring na vraag 19] 
 
18A. Het u die afgelope 12 maande so ’n toestel gebruik?  Ja  1 79 
Nee  2 
 
19. Het u al ooit so gesukkel met asemhalingsprobleme Ja  1 80 
dat dit met u gewone daaglikse aktiwiteite ingemeng het, Nee  2 
of gemaak het dat u nie kon werk nie? 
 
[Indien ja, vra vraag 19A. Indien nee, spring na vraag 20] 
 
19A. Hoeveel sulke episodes het u die afgelope  episodes 81 
12 maande beleef? 
 
[Indien 19A >0, vra vraag 19B en 19C, spring andersins na vraag 20] 
 
19B. Vir hoeveel van die episodes die afgelope  episodes 82 
12 maande was dit nodig om ’n dokter te sien? 
 
19C. Vir hoeveel van die episodes die afgelope   episodes 83 
12 maande is u gehospitaliseer? 
 
[Indien 19C >0,  vra vraag 19C1, spring andersins na vraag 20] 
 
19C1. Vir hoeveel volle dae is u die afgelope     days  84 
12 maande vir asemhalingsprobleme gehospitaliseer? 
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Tabakrook 
 
Nou gaan ek u uitvra oor rook. Eers gaan ek oor sigarette vra. 
 
20. Het u al ooit sigaret gerook?  Ja  1 85 
Nee  2 
 
(“Ja,” beteken meer as 20 pakkies sigarette in ’n leeftyd of ’n jaar lank meer as 1 sigaret elke dag) 
 
[Indien ja, vra vraag 20A tot by 20D; spring andersins na vraag 22) 
 
20A. Hoe oud was u toe die eerste keer gereeld                 __________ jaar oud 86 
sigaret begin rook het? 
 
20B. Indien u ophou rook het, hoe oud was                          __________ jaar oud     87
 u toe u die laaste keer opgehou het? 
 
 
20C. Gemiddeld hoeveel sigarette per dag __________ sigarette/dag 88 
rook u (het u gerook) oor die hele tydperk 
wat u rook (gerook het)? 
 
20D. Gemiddeld oor die hele tydperk wat u Klaar vervaardig  1 89 
rook (gerook het), rook (het) u hoofsaaklik                Handgerol    2 
klaar vervaardigde of handgerolde sigarette (gerook)? 
 
[Indien die deelnemer tans sigaret rook (vraag 20B nie ingevul), vra dan vraag 21A en 21B.  Spring 
andersins na vraag 22] 
 
21A. Hoeveel keer die afgelope jaar het u vir _______ keer  90 
minstens 24 uur ophou rook? 
 
21B. Oorweeg u dit ernstig om op te hou rook? Ja, binne die volgende 30 dae  1
 91 
Ja, binne die volgende 6 maande  2 
Nee, dink nie aan ophou nie  3 
 
22. Het u al ooit pyp of sigare gerook?  Ja  1 92 
Nee  2 
[Iniden ja, vra vraag 22A.  Indien nee, gaan aan met vraag 23] 
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22A. Rook u tans pyp of sigare?  Ja  1 93 
Nee  2 
 
[Indien die respondent nog nooit gerook het nie (dus “nee” geantwoord het op beide vraag 20 en 22), 
spring dan na vraag 25.  Gaan andersins aan met vraag 23] 
 
23. Het ’n dokter of ander gesondheidsorgverskaffer Ja  1 94 
u al ooit aangeraai om op te hou rook?  Nee  2 
 
[Indien ja, vra vraag 23A en 23B.  Indien nee, spring na vraag 24] 
 
23A. Is u in die afgelope 12 maande aangeraai  Ja  1 95 
om op te hou rook? Nee  2 
 
23B. Het u enige medikasie (op voorskrif of daarsonder) Ja  1 96 
gebruik om u te help ophou rook? Nee  2 
 
[Indien ja, vra eers vraag 23B1 en dan vraag 24.  Indien nee, spring na vraag 24] 
 
23B1.Watter soort medikasie het u geneem  Nikotienvervanging   1 97 
om u te help ophou rook?  Buproprion   2 
Tofranil   3 
Ander   4 
 
24. Het u enige iets anders gedoen  Ja   1 98 
om u te help om op te hou rook? Nee   2 
 
[Indien ja, vra vraag 24A, spring andersins na vraag 25] 
 
24A. Wat het u gebruik of gedoen?  Hipnose   1 99 
Akupunktuur   2 
Bioterugvoering   3 
Ander   4 
 
Beroepsblootstelling 
 
25. Het u al ooit ’n jaar of langer stowwerige werk gedoen? Ja  1 100 
Nee  2 
 
[Indien ja, vra vraag 25A, spring andersins na vraag 26] 
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25A. Hoeveel jaar lank het u op stowwerige plekke gewerk?             _______ jaar 101 
 
Bykomende siektetoestande 
 
26. Het ’n dokter of ander gesondheidsorgverskaffer al ooit vir u gesê u het: 
 
 
26A. ’n Hartkwaal  Ja  1 102 
Nee  2 
 
26B. Hipertensie Ja  1 103 
Nee  2 
 
26C. Diabetes  Ja  1 104 
Nee  2 
 
26D. Longkanker  Ja  1 105 
Nee  2 
 
26E. Beroerte  Ja  1 106 
Nee  2 
 
26F. Tuberkulose  Ja  1 107 
Nee  2 
 
[Indien ja op 26F, vra dan 26F1; spring andersins na vraag 27] 
 
26F1. Neem u tans medisyne vir tuberkulose?  Ja  1 108 
Nee  2 
[Indien nee op 26F1, vra dan 26F2; spring andersins na vraag 27] 
 
26F2. Het u al ooit medisyne gebruik vir tuberkulose?  Ja  1 109 
Nee  2 
 
27. Het u al ooit ’n operasie op u borskas ondergaan waarin Ja  1 110 
’n deel van u long verwyder is? Nee  2 
 
28. Is u as kind vir asemhalingsprobleme gehospitaliseer Ja  1 111 
voor u 10 jaar oud was? Nee  2 
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29. Het u die afgelope 12 maande ’n griepinspuiting gekry?  Ja  1 112 
Nee  2 
 
30. Het ’n dokter of ander gesondheidsorgkundige al vir u vader, Ja  1 113 
moeder, suster of broer gesê dat hulle met emfiseem, chroniese Nee  2 
brongitis of chronies obstruktiewe longsiekte gediagnoseer is? 
 
31. Het enige iemand wat in u huis woon (behalwe uself) die afgelope  Ja  1
 114 
twee weke ’n sigaret, pyp of sigaar in die huis gerook? Nee  2 
 
 
SF-12 
 
Onderhoudvoerder: Lees die volgende instruksies voor aan die deelnemer. 
 
INSTRUKSIES:  Dié opname wil weet wat u siening omtrent u gesondheid is. Die inligting help tred 
hou met hoe u voel en hoe goed u in staat is om u daaglikse aktiwiteite uit te voer. Beantwoord telkens 
die vraag deur die antwoord af te merk soos aangedui word. Antwoord asseblief so goed u kan as u nie 
seker is wat om te antwoord nie. 
 
32. Sou u oor die algemeen sê u gesondheid is:  (Merk een af.) Uitstekend  1
 115 
Baie goed  2 
Goed  3 
Redelik  4 
Swak  5 
 
33. Die volgende items handel oor aktiwiteite wat u dalk op ’n tipiese dag sou uitvoer. 
Beperk u gesondheid u tans in die uitvoer daarvan? Indien wel, in watter mate? 
 
33A. Matige aktiwiteite, soos om ’n tafel       Ja, beperk my baie  1 116 
rond te skuif, ’n stofsuier te stoot,  Ja, beperk my effens  2 
rolbal te speel, of gholf te speel Nee, beperk my glad nie  3 
 
 
33B. Om etlike stelle trappe te klim   Ja, beperk my baie  1  117 
Ja, beperk my effens   2 
Nee, beperk my glad nie  3 
 
34. Het u die afgelope 4 weke enige van die volgende probleme ondervind met u werk 
of enige ander gereelde daaglikse aktiwiteit as gevolg van u fisieke gesondheid? 
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34A. Minder bereik  as wat u sou wou   Ja  1  118 
Nee  2 
 
34B. Was beperk ten opsigte van tipe werk of ander aktiwiteite  Ja  1 
 119 
Nee  2 
 
35. Het u die afgelope 4 weke enige van die volgende probleme ondervind met u werk 
of ander daaglikse aktiwiteite as gevolg van enige emosionele probleem (soos om 
depressief of angstig te voel)? 
 
35A. Minder bereik  as wat u sou wou   Ja  1  120 
Nee  2 
 
35B. Het die werk of ander aktiwiteit nie so nougeset as gewoonlik 
gedoen nie   Ja  1  121 
Nee  2 
 
36. In watter mate het pyn die afgelope 4 weke ingemeng met  Glad nie  1
  122 
u gewone werk (dit sluit werk buite die huis sowel as huiswerk in)?  Effens  2 
Redelik  3 
Taamlik baie  4 
Uitermatig baie  5 
 
37. Hierdie vrae het te doen met hoe u gevoel het en hoe dit met u gesteld was die afgelope 4 
weke.  Gee vir elke vraag asseblief telkens die een antwoord wat die beste beskryf hoe u gevoel het. 
 
Hoe dikwels die afgelope 4 weke… 
 
37A. Het u kalm en rustig gevoel?   Heeltyd  1  123 
Gewoonlik  2 
Dikwels  3 
Somtyds  4 
Selde  5 
Nooit  6 
 
37B. Het u baie energiek gevoel?   Heeltyd  1  124 
Gewoonlik  2 
Dikwels  3 
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Somtyds  4 
Selde  5 
Nooit  6 
 
 
 
 
 
37C. Het u mismoedig en terneergedruk gevoel?  Heeltyd  1  125 
Gewoonlik  2 
Dikwels  3 
Somtyds  4 
Selde  5 
Nooit  6 
 
38. Hoe dikwels die afgelope 4 weke het u fisieke gesondheid   Heeltyd  1 
 126 
of emosionele probleme ingemeng met u sosiale  Gewoonlik  2 
aktiwiteite (soos om by vriende of familie  Dikwels  3 
te kuier, en so meer)?  Somtyds  4 
Selde  5 
Nooit  6 
 
 
Kopiereg © XXXX Medical Outcomes Trust. Alle regte voorbehou.   (SF-12 Standaard Amerikaanse 
Weergawe 2.0) 
 
 
EKONOMIESE IMPAK 
 
Verlore werksdae 
 
Die volgende vrae gaan oor werk en tye wat u dalk weens u asemhalingsprobleme nie kon werk nie. 
 
39. Het u in enige stadium die afgelope 12 maande gewerk vir ’n inkomste?  Ja  1
 127 
Nee  2 
[Indien nee, gaan voort met vraag 39A; indien ja, spring na vraag 40] 
 
39A. Het u die afgelope 12 maande hoofsaaklik weensJa  1 128 
asemhalingsprobleme nooit vir ’n inkomste gewerk nie? Nee  2 
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39B. Het u die afgelope 12 maande nooit vir ’n inkomste gewerk nie Ja  1 129 
omdat u ’n voltydse tuisteskepper of versorger was? Nee  2 
 
[Indien ja, gaan voort met vraag 39C, indien nee, spring na vraag 44] 
 
39C. Het gesondheidsprobleme u die afgelope 12 maande verhoed Ja  1 130 
om die gewone pligte van ’n tuisteskepper/versorger uit te voer?   Nee  2 
 
[Indien ja, gaan voort met vraag 39D en 39E, indien nee, spring na vraag 44] 
 
39D. Hoeveel volle dae die afgelope 12 maande was u weens _______ dae  131 
gesondheidsprobleme nie in staat om u pligte as 
tuisteskepper/versorger uit te voer nie? 
 
39E. Hoeveel volle dae die afgelope 12 maande was u spesifiek _______ dae 
 132 
weens asemhalingsprobleme nie in staat om u pligte as 
tuisteskepper/versorger uit te voer nie? 
 
[Spring asseblief na vraag 44] 
 
40. Hoeveel maande uit die afgelope 12 maande _____ maande 133 
het u vir ’n inkomste gewerk? 
 
41. In die maande wat u gewerk het, hoeveel dae per week _____ dae 134 
het u vir ’n inkomste gewerk? 
 
42. Hoeveel uur per dag werk u gewoonlik vir ’n inkomste?    ______ uur 135 
 
43. Het u gesondheidsprobleme u die afgelope 12 maande daarvan Ja  1 136 
weerhou om vir ’n inkomste te werk?  Nee  2 
 
[Indien ja, gaan voort met vraag 43A en 43B, indien nee, spring na vraag 44] 
 
43A. Hoeveel volle dae was u die afgelope 12 maande weens u _______ dae 
 137 
gesondheidsprobleme nie in staat om vir ’n inkomste te werk nie? 
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43B. Hoeveel volle dae was u die afgelope 12 maande spesifiek weens _______ dae
  138 
asemhalingsprobleme nie in staat om vir ’n inkomste te werk nie? 
 
 
Niewerkaktiwiteite nie bygebring 
 
Die volgende vrae handel oor tye wat u moontlik weens u asemhalingsprobleme nie u normale 
aktiwiteite kon bybring nie (soos om inkopies te doen, vriende/familie te besoek, kerk toe te gaan, of 
ander aktiwiteite). 
 
44. Het u die afgelope 12 maande weens gesondheidsprobleme nie Ja  1 139 
aan een of meer niewerkverwante aktiwiteit deelgeneem nie?   Nee  2 
 
[Indien ja, gaan voort met vraag 44A en 44B, indien nee, spring na vraag 45] 
 
44A. Hoeveel volle dae het u die afgelope 12 maande  _______ dae  140 
weens u gesondheidsprobleme nie deelgeneem nie aan 
aktiwiteite wat nie werkverwant is nie? 
 
44B. Hoeveel volle dae het u die afgelope 12 maande  _______ dae  141 
spesifiek weens asemhalingsprobleme nie deelgeneem nie 
aan aktiwiteite wat nie werkverwant is nie? 
Respiratoriese simptome en siektetoestande 
 
Die volgende vrae handel oor simptome wat met u asemhaling of u borskas verband hou. Die vrae 
klink dalk soos vorige vrae, maar antwoord asseblief so goed u kan. Indien u twyfel of u ja of nee 
moet sê, antwoord dan asseblief nee. 
 
Hoes 
 
45A. Het u die afgelope 12 maande gehoes Ja  1 142 
terwyl u nie verkoue gehad het nie? Nee  2 
 
 
45B. Het u die afgelope 12 maande vroegoggende gehoes of Ja  1 143 
gehoes sodra u opgestaan het? Nee  2 
 
[Indien nee op BEIDE vraag 45A en 45B, spring na vraag 46.  Indien ja op 45A of 45B, antwoord die 
volgende:] 
 
45C. Het u die afgelope 12 maande vir drie maande Ja  1 144 
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of langer dié hoes op die meeste dae gehad? Nee  2 
 
45D. Hoeveel jaar lank het u al die hoes?  ______ jaar  145 
 
Slym 
 
46A. Het u die afgelope 12 maande slym uit u bors Ja  1 146 
opgehoes behalwe wanneer u verkoue was?  Nee  2 
 
46B. Het u die afgelope 12 maande vroegoggend of sodra u 
opgestaan het slym uit u bors opgehoes? Ja  1 147 
Nee  2 
 
[Indien nee op BEIDE 46A en 46B, spring na vraag 47.  Indien ja op 46A of 46B, antwoord die 
volgende:] 
 
46C. Het u die afgelope 12 maande vir drie maande of langer Ja  1 148 
op die meeste dae slym uit u bors opgehoes?   Nee  2 
 
46D. Hoeveel jaar lank het u so slym uit u bors opgehoes?                ______ years  149 
 
Hoes- en slymepisodes 
47A. Het u die afgelope 12 maande periodes of episodes beleef waarin Ja  1 150 
u ’n hoes met slym gehad het wat ’n week of langer aangehou het? Nee  2 
(Indien u hoes gewoonlik met slym gepaard gaan, moet u asseblief 
net periodes of episodes tel wat met ’n groter gehoes en meer slym 
gepaard gegaan het.) 
[Indien nee, spring na VOLTOOI DEUR aan die einde van die vraelys. Indien ja, antwoord die 
volgende:] 
47B. Nagenoeg hoeveel sulke episodes het u  ______ episodes 151 
die afgelope 12 maande gehad? 
47C. Hoeveel jaar lank al het u minstens een   ______jaar  152 
so ’n episode per jaar? 
Voltooi deur: ____ ____ ____ ____ 153 
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Appendix B-5: 6MWT Check List 
6MWT Procedure Check list  
PATIENT INFORMATION  
A light meal is acceptable before the test is conducted  
Patient should not have done any vigorous exercise 2 hours prior to the commencement of the test  
Document any medication used  
SAFETY – Precautions and contraindications  
Vascular compromise eg DVT  
Cardiac compromise: atrial fibrillation; tachycardia; unstable BP  
Pulmonary compromise: SATS < 92  
PATIENT PREPARATION  
Comfortable clothing should be worn  
Appropriate shoes for walking should be worn (Otherwise, bare foot)  
Patient should use their usual walking aids while performing the test (cane, walker etc)  
PREPARATION  
Mark out distance of 30 meters in a walkway or hall/gym in 5m increments using tape against the wall or 
on the floor 
 
Use cones to indicate starting and turning points  
Ensure 40% O2 mask is available   
Explain the Modified BORG Scale (measurements are taken before, immediately after and again 2 minutes 
after the test was performed) 
 
MEASUREMENTS   
Document time of 6MWT  
Position the patient in a chair near the starting point for at least 5 minutes before the test  
During this time  
Check for any cardiac or pulmonary instability which would compromise walking ability  
Check that the patient is suitably dressed (clothing and shoes) for test  
Measure pulse rate and breath rate at rest  
Patient then stands and is asked to rate their baseline dyspnoea and overall fatigue using the BORG Scale  
TESTING PROCEDURE  
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Set the lap counter and timer to zero  
Assemble all necessary equipment (lap counter, timer, clipboard, Borg Scale) and move to starting point  
Position the patient at the starting line  
Instruct the patient about the testing procedure using the standardized script  
Do not talk to anyone during the test. Use an even tone of voice when using standardized encouragement 
phrases 
 
Each time the patient returns to the starting point, click the lap counter once and let the patient see you 
doing it 
 
Watch the patient at all times. Do not get distracted during the test  
Only use the scripted encouragement every minute using an even tone  
When timer rings or buzzes, say “STOP!” and walk to where the patient has stopped  
Take a chair to the patient if the patient seems exhausted  
Mark the spot where the patient has stopped by placing a piece of tape on the floor  
POST TEST PROCEDURE  
Record the post test BORG dyspnoea and fatigue levels. Remind the patient of the pre test scores and ask 
them to compare 
 
Ask the patient “What, if anything, kept you from walking further?”  
Record pulse rate and breath rate  
Document the laps from the lap counter. Measure the remaining distance (round up)  
Wait 2 mins and record the pulse rate and breath rate again  
PROCEDURE IF PATIENT STOPS BEFORE 6 MINUTES  
Mark the spot where the patient stopped by placing a piece of tape on the floor  
Do not stop the timer  
Use scripted words to instruct patient  
Place the patient in a chair  
Patient decided if/when they want to continue. Continue using the scripted text when counting down 6 
minutes 
 
If patient is unable to continue (physiotherapists assessment) note on the worksheet the distance, the time 
stopped and the reason for stopping prematurely 
 
Also document pulse rate, breath rate and fatigue and dyspnoea (BORG scale) scores  
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Appendix B-6 & B-7: 6MWT Instructions English and Afrikaans 
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Appendix B-8: 6MWT Data Collection Sheet 
6MWT Data Collection Sheet 
Measurements Baseline End of Test 2 min after Test 
Time 
 
 
   
Heart Rate 
 
 
   
Breath Rate 
 
 
   
Dyspnoea (BORG Scale) 
 
 
   
Fatigue (Borg Scale) 
 
 
   
    
Lap Conter: Number of 
laps x60 meters 
completed 
   
Partial laps 
completed(Total rounded 
up) 
   
Total 
 
 
   
  
Patient stopped before 6 minutes?       YES / NO 
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Reason: 
Chest Pain    Intolerable Dyspnoea    Leg Cramps 
Staggering    Diaphoresis 
 
What prevented you from walking further? 
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------- 
Symptoms at the end of exercise?       YES / NO 
 
Angina     Dizziness    Hip/Leg/Calf Pain 
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Appendix B-9: BMI Data collection sheet 
BMI DATA COLLECTION SHEET AND MEDICATION ADMINISTRATION SHEET 
Patient Reference Number 
……………………………………………………………………………… 
 
Gender:    Male    Female 
Age: ………………………………………………………………………… 
 
Weight (kg): ………………………………………………………………... 
 
Height (cm): ………………………………………………………………... 
 
Body Mass Index (kg/m2 ): ………………………………………………… 
 
Medication: 
 
Time Administered: ………………………………………………………… 
 
 
Dosage:  2 Puffs of MDI   
 
Side Effects experienced:   Yes    No   
 
 
If yes, describe side effects: 
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………… 
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Appendix B-10: Modified BORG Scale   
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Appendix C-1: Associations between spirometry and symptoms of cough 
 
The study sample were categorized into respondents who answered ‘yes’ and respondents who answered 
‘no’ to the questions of: “Cough without having a cold”, “Cough for longer than 3 months”, “Current 
Smoker” and “Worked in a dusty job”. These 4 categories were compared with the FVC, FVC (%Pred), 
FEV1, FEV1 (%Pred), FEV1/FVC and FEV1/FVC (%Pred). ANOVA was used to analyse data and detect 
any differences between ‘yes’ and ‘no’ groups. 
Cough without having a cold  
FVC: Cough without Cold
Current effec t: F(1, 42)=2.6632, p=0.11 Mann-Whitney  U p=0.16
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FVC % Predicted: Cough without Cold
Current effect: F(1, 42)=2.1709, p=0.15 Mann-Whitney U p=0.40
Vertical bars denote 0.95 confidence intervals
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FEV1: Cough wi thout Cold
Current effec t: F(1, 42)=2.4993, p=0.12 M ann-Whitney  U p=0.14
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cough without cold; LS Means
Current effect: F(1, 42)=.73717, p=0.40 Mann-Whitney U p=0.71
Vertical bars denote 0.95 confidence intervals
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cough without cold; LS Means
Current effect: F(1, 42)=.76379, p=0.39 Mann-Whitney U p=0.58
Vertical bars denote 0.95 confidence intervals
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cough without cold; LS Means
Current effect: F(1, 42)=.92443, p=0.34 Mann-Whitney U p=0.37
Vertical bars denote 0.95 confidence intervals
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There was no significant difference between the groups with regards to spirometry results. Patients who 
coughed without having a cold did however show a decrease in FVC (F(1;42)=2.66;p=0.11), a decrease 
in FEV1(F(1;42)=2.49;p=0.12) and a decrease in FEV1/FVC (F(1;41)=0.76;p=0.39). 
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Cough for longer than 3 months  
Cough 3 months; LS Means
Current effect: F(1, 27)=1.7619, p=0.20 Mann-Whitney U p=0.18
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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Cough 3 months; LS Means
Current effect: F(1, 27)=.32792, p=0.57 Mann-Whitney U p=0.50
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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Cough 3 months; LS Means
Current effect: F(1, 27)=.00021, p=0.99 Mann-Whitney U p=0.71
Effective hypothesis  decomposition
Vertical bars denote 0.95 confidence intervals
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Cough 3 months; LS Means
Current effect: F(1, 27)=.19750, p=0.66 Mann-Whitney U p=0.47
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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Cough 3 months; LS Means
Current effect: F(1, 27)=.25210, p=0.62 Mann-Whitney U p=0.35
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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For patients who coughed longer than three months, there was also no significant difference between 
the groups. However, those who coughed for more than three months showed a decrease in FVC 
(F(1;27)=1.76;p=0.20) as well as a decrease in FEV1 (F(1;27)=0.33;p=0.57).  
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Smoked Cigarettes  
smoked cigarettes; LS Means
Current effect: F(1, 42)=.72447, p=0.40 Mann-Whitney U p=0.60
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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smoked cigarettes; LS Means
Current effect: F(1, 42)=.01175, p=0.91 Mann-Whitney U p=0.44
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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smoked cigarettes; LS Means
Current effect: F(1, 42)=.01007, p=0.92 Mann-Whitney U p=0.92
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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smoked cigarettes; LS Means
Current effect: F(1, 42)=1.8400, p=0.18 Mann-Whitney U p=0.17
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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smoked cigarettes; LS Means
Current effect: F(1, 42)=.94100, p=0.34 Mann-Whitney U p=0.23
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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smoked cigarettes; LS Means
Current effect: F(1, 42)=.36369, p=0.55 Mann-Whitney U p=0.60
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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No significant difference was found between smokers and non smokers. However, smokers showed a 
decrease in FEV1 (%Pred) (F(1;42)=1.84;p=0.18) as well as FEV1/FVC (% Pred) 
(F(1;42)=0.36;p=0.55) 
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Occupational Dust Exposure  
worked dusty job; LS Means
Current effect: F(1, 42)=.69291, p=0.41 Mann-Whitney U p=0.48
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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worked dusty job; LS Means
Current effect: F(1, 42)=2.2589, p=0.14 Mann-Whitney U p=0.35
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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worked dusty job; LS Means
Current effect: F(1, 42)=.00002, p=1.00 Mann-Whitney U p=0.95
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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worked dusty job; LS Means
Current effect: F(1, 42)=2.4559, p=0.12 Mann-Whitney U p=0.18
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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worked dusty job; LS Means
Current effect: F(1, 42)=2.1044, p=0.15 Mann-Whitney U p=0.14
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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worked dusty job; LS Means
Current effect: F(1, 42)=.67287, p=0.42 Mann-Whitney U p=0.64
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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 Once again, there were no significant differences between those who worked in a dusty job for longer 
than 1 year versus those who did not. However, those who were exposed to occupational dust showed a 
decrease in FEV1 (%Pred) (F(1;42)=2.45;p=0.12), a decrease in FEV1/FVC and FEV1/FVC (%Pred) 
(F(1;42)=2.10;p=0.15 and F(1;42)=0.67;p=0.42) respectively. 
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Appendix C-2: Associations of PCS and MCS with 6MWD 
 
Pearsons Corr 6MWD x20m vs PCS =0.366 
 
Pearsons Corr 6MWD x20m vs MCS = 0.537 
 
R² = 0.1341
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Pearsons Corr 6MWD x10m vs PCS = 0.174 
 
Pesrsons Corr 6MWD x10m vs MCS = -0.093 
 
 
 
 
 
 
 
 
 
 
Appendix C-3: PCS and MCS association with 6MWD 
 
R² = 0.0087
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Spreadsheet2 in results_2.stw 148v*45c
  6MWT:6MWD (m):PCS:   r = 0.1125, p = 0.4673
 Spearman r = 0.13 p=0.40
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Spreadsheet2 in results_2.stw 148v*45c
  6MWT:6MWD (m):MCS:   r = 0.1183, p = 0.4443
 Spearman r = 0.05 p=0.76
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Appendix C-4: Age and BMI association with 6MWD 
 
 
Spreadsheet2 in results_2.stw 134v*45c
  DEMOGRAPHICS: 3.Age:6MWT:6MWD (m):   r = -0.1668, p = 0.2793
 Spearman r = -0.05 p=0.76
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Spreadsheet2 in results_2.stw 134v*45c
  BMI:6MWT:6MWD (m):   r = -0.1125, p = 0.4617
 Spearman r = -0.02 p=0.92
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Appendix C-5: Full Spirometry with GOLD Classification 
Refer
ence 
SPIROME
TRY:FVC 
SPIROMETRY
:FVC_PRED 
SPIROMETR
Y:FVC_(% 
PREDICTED) 
SPIROMET
RY:FEV1 
SPIROMETRY:
FEV1_PRED 
SPIROMETR
Y:FEV1_(% 
PREDICTED) 
SPIROMETRY
:FEV1/FVC 
SPIROMETRY:FE
V1/FVC_PRED 
SPIROMETRY:F
EV1/FVC_(% 
PREDICTED) 
GOLD 
Stage 
Classifi
cation 
**1 3.66 3.61 101.385 3.25 3.15 103.174 90.3 84.16 107.295  
**2 4.45 4.74 93.881 3.89 4 97.25 87.4 82.71 105.670  
12*1 2.35 2.7 87.037 1.8 2.32 77.586 76.6 82.26 93.119  
12*2 2.17 2.84 76.408 1.89 2.46 76.829 87.1 83.4 104.436  
12*3 2.73 4.29 63.636 1.94 3.34 58.083 71.1 76.05 93.491  
12*4 3.39 3.09 109.708 2.53 2.62 96.564 74.6 79.65 93.659  
12*5 2.9 3.64 79.670 1.35 3.07 43.973 46.6 79.83 58.374 Stage 3 
12*6 3.99 2.84 140.492 3.54 2.54 139.370 88.7 91.77 96.654  
12*7 3.74 2.15 173.953 3.31 1.82 181.868 88.5 80.74 109.611  
12*8 2.96 2.53 116.996 2.08 2.17 95.852 65 78.93 82.351 Stage 1 
12*9 2.13 3.06 69.607 1.6 2.53 63.241 75.1 78.21 96.023  
12*1
0 1.98 2.28 86.842 1.53 1.94 78.865 77.2 80.17 96.295  
12*1
1 2.48 2.8 88.571 1.31 2.4 54.583 52.8 81.12 65.088 Stage 2 
12*1
2 1.63 2.39 68.200 0.98 2.03 48.275 60.1 79.79 75.322 Stage 3 
12*1
3 2.44 3.32 73.493 2.07 2.74 75.547 84.8 78.03 108.676  
12*1
4 2.07 2.44 84.836 1.55 2.09 74.162 74.9 81.5 91.901  
12*1
5 2.45 3.28 74.695 1.78 2.66 66.917 72.7 77.49 93.818  
12*1
6 2.97 4.39 67.653 2.14 3.67 58.310 72.1 81.27 88.716  
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12*1
7 3.13 3.35 93.432 2.1 2.82 74.468 67.1 79.65 84.243 Stage 1 
12*1
8 3.17 3.67 86.376 2.76 3.11 88.745 87.1 80.91 107.650  
12*1
9 1.98 2.54 77.952 1.79 2.18 82.110 90.4 81.31 111.179  
12*2
0 3.89 4.74 82.067 2.98 3.87 77.002 76.6 79.47 96.388  
12*2
1 1.63 3.2 50.937 0.95 2.53 37.549 58.3 76.05 76.660 Stage 3 
12*2
2 2.74 3.38 81.065 2.18 2.94 74.149 79.6 83.59 95.226  
12*2
3 2.88 3.62 79.558 2.53 3 84.333 87.8 79.29 110.732  
12*2
4 3.14 3.15 99.682 2.75 2.75 100 87.6 84.35 103.852  
12*2
5 3.85 4.29 89.743 3.55 3.59 98.885 92.2 81.27 113.448  
12*2
6 2.82 4.58 61.572 2.22 3.79 58.575 78.7 80.73 97.485  
12*2
7 2.05 2.74 74.817 1.1 2.37 46.413 55.6 82.64 67.279 Stage 3 
12*2
8 3.11 4.06 76.600 2.53 3.24 78.086 81.4 77.49 105.045  
           
12*3
0 2.01 4.06 49.507 0.94 3.32 28.313 46.8 79.11 59.158 Stage 4 
12*3
1 3.92 4.27 91.803 2.78 3.46 80.346 70.9 78.75 90.031  
12*3
2 3.45 4.32 79.861 3.15 3.59 87.743 91.3 80.73 113.093  
12*3
3 3.19 5.05 63.168 1.84 4.23 43.498 57.7 82.71 69.761 Stage 3 
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12*3
4 2.62 2.98 87.919 1.96 2.56 76.562 74.8 80.36 93.081  
12*3
5 2.53 3.24 78.086 2.02 2.81 71.886 79.8 82.45 96.785  
12*3
6 2.93 3.34 87.724 2.52 2.9 86.896 86 82.64 104.065  
12*3
7 3.47 5.06 68.577 2.69 4.19 64.200 77.5 81.63 94.940  
12*3
8 3.56 3.14 113.375 2.97 2.77 107.220 83.8 81.99 102.207  
12*3
9 2.71 2.81 96.441 2.34 2.42 96.694 86.3 81.88 105.398  
12*4
0 5.2 4.65 111.827 4.43 3.88 114.175 85.1 81.63 104.250  
12*4
1 2.94 3.61 81.440 2.24 3.15 71.111 76.2 83.21 91.575  
12*4
2 2.67 3.24 82.407 2.08 2.79 74.551 77.9 80.17 97.168  
12*4
3 2.27 3.84 59.114 1.33 3.2 41.562 58.6 80.19 73.076 Stage 3 
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Appendix C-6: Pilot Study Data (Lung Function) 
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Appendix C-7: Spirometer Calibration 
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